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ABSTRACT 
 
Progression to castrate resistant prostate cancer (CRPC) is associated 
with high morbidity. Disease recurrence and progression is influenced by the 
tumor microenvironment. Resident and recruited stroma contribute to cancer 
progression through paracrine signaling. A conditional stromal TGF- type II 
receptor knockout mouse model (Tgfbr2fspKO) was characterized to be a model 
for understanding CRPC progression. We demonstrated the resident stromal 
fibroblast responsiveness to TGF- mediated paracrine canonical Wnt signaling 
in the adjacent prostate epithelia in castrate resistance. Regrowth of the prostate 
was associated with recruitment of stromal cells from the bone marrow and a 
contributor to CRPC. We determined that a population of bone marrow derived 
cells, particularly the mesenchymal stem cells (MSCs), were recruited and fused 
to prostatic ductal epithelia. These MSCs were found to be a source of Wnt 
ligands that could contribute to castrate resistant prostatic epithelia. In summary, 
the tumor microenvironment composed of both resident and recruited stromal 
cells mediate CRPC through paracrine signaling. 
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PREFACE 
 
Of all the ailments that affect our society, cancer is among those that bring 
the most fear. Perhaps this is because it affects everyone on the planet either 
directly or indirectly. Cancer is commonly described as an accumulation of 
diseases in which cells within the body grow uncontrollably. This definition seems 
elusive and rightly so as we have just begun to grasp the complexities in an effort 
to treat and prevent its inception. There are many types and sub-classifications of 
cancer, which continue to expand as we are able to distinguish the differences 
among these. This may seem daunting when the number one correlate with 
cancer is aging and our society continues to have an increase in the elderly 
population. Despite this, there have been many advances toward therapies to 
treat cancer due to the ongoing research efforts. Although a cure to treat all 
cancers may not be possible, it is hopeful that multiple treatments will be 
developed in the future to treat each individual cancer. 
This thesis focuses on understanding castrate resistant prostate cancer 
(CRPC). The majority of men with prostate cancer can be treated by surgical 
resection or radiation therapy if they are diagnosed early. Unfortunately, the 
development of CRPC is inevitable for some unlucky individuals. Within this 
thesis we focus on the stroma as it contributes to CRPC. As seen in our studies, 
knowledge obtained from the initial studies on the resident stroma served as a 
basis for understanding the contribution of the recruited stroma in the prostate. 
We show in the first group of studies through various transgenic mouse models, 
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the importance of resident stromal TGF- signaling and how this contributes to 
CRPC. Based on our Tgfbr2fspKO mouse model we showed how the loss of 
stromal TGF- signaling led to enhanced stromal Wnt production. Through 
paracrine signaling these Wnt ligands caused transformation of the epithelia and 
castrate resistance. SFRP-2 treatment to inhibit Wnt signaling restored the 
castrate response and slowed CRPC progression. In the second group of studies 
we focus on recruited stroma and how this also led to the progression of CRPC. 
BMDCs were recruited and incorporated into the prostate epithelia during 
regrowth. MSCs were responsible for this incorporation through fusion. In CRPC, 
recruited MSCs were shown to enhance Wnt signaling in CRPC tumor epithelia. 
Overexpression of SFRP-2 in MSCs recruited to the tumors suppressed the 
enhanced Wnt signaling and caused tumor associated apoptosis and necrosis. 
Together, these studies highlight the importance of understanding how 
components of the tumor microenvironment enhance cancer progression, with a 
focus on the resident and recruited stroma.  
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CHAPTER I 
 
INTRODUCTION 
 
Prostate Anatomy and Function 
The prostate is a male accessory reproductive organ located just below 
the bladder and in front of the rectum (Figure 1). While it is not an essential 
organ, it greatly enhances male fertility by producing a zinc, citric acid, fructose, 
and prostate-specific antigen (PSA) containing fluid to further liquefy the semen 
(consisting of sperm and seminal fluid) as it is ejaculated through the urethra. 
The urethra traverses the prostate and continues through the penis. In humans 
the prostate is divided into three anatomic regions (the central zone, the 
transitional zone, and the peripheral zone), which differentially correspond to 
prostate disease. The central zone is not commonly associated with prostatic 
disease. The transitional zone is the primary site that develops benign prostatic 
hyperplasia (BPH) with many symptoms including weak or interrupted urine flow 
as the prostate can grow inward narrowing the urethra. Development of BPH is 
estimated to occur as early as age 30 (Verhamme, Dieleman et al. 2002). Most 
men will develop BPH if they live long enough; however there does not seem to 
be a connection between BPH and prostate cancer development. The peripheral 
zone is the site of most prostate cancers, and symptoms are often not apparent 
until late stages of cancer development. For this reason, digital rectal exams are  
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Figure 1. Prostate location in the male body. The human prostate is shown 
centrally located in yellow. The bladder is on top of the prostate (beige) and the 
ureter runs from the prostate through the penis (brown). (Image taken from 
www.pillsforall.com). 
3 
useful as the cancer may be identified by abnormalities such as nodules or 
hardened tissue within the organ.  
In murine models, the prostate is divided into lobes as opposed to zones. 
There is no definitive correlation between the lobes in mice with the zones of the 
human prostate. Although the gross anatomical structure is different, the 
secretory function and thus secretory glands of humans and mice share many 
similarities. Transgenic mouse models, therefore, serve as the gold standard for 
mechanistic understanding of human prostate cancer development and 
progression.  
 
Prostate Glandular Structure 
 
 The secretory glandular structure of the prostate is composed of 
organized epithelia surrounded by a basement membrane and fibromuscular 
stroma (Figure 2) (Cunha, Hayward et al. 2002). Prostatic homeostasis requires 
paracrine signals from the fibromuscular stroma to the epithelia and vice versa to 
maintain growth quiescence. These studies will focus on prostate cancer 
paracrine signaling, which consists of one cell type communicating with another 
cell type (ex: stromal- epithelial signaling). There are many parallels to prostate 
development. Human and mouse fibromuscular stroma is made up of a 
heterogeneous mixture of mainly smooth muscle cells and some fibroblasts and 
myofibroblasts. The human prostate stromal compartment, however, has a 
greater ratio of stroma to epithelia compared to mice. Developmental parallels  
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Figure 2. Prostate glandular structure. The epithelial cells (blue rounded 
rectangles) compose the glandular structure. The stroma (pink half moons) 
surround the epithelial glands. Not shown is the basement membrane between 
the epithelial and stromal layers. Prostatic fluids are secreted into the lumen 
(empty space in the center of the gland). 
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will be discussed where appropriate, although there are far too many to discuss 
in depth. An overview of paracrine signaling in prostate development can be 
reviewed in the many articles by the pioneering father of this field, Gerald Cunha 
(Cunha, Ricke et al. 2004; Cunha 2008). Proper epithelial differentiation is 
necessary for the production of prostatic fluid to enhance sperm survival in the 
female reproductive tract. This alkaline prostatic fluid serves to counteract the 
acidic environment exiting the male urethra and within the vagina producing a 
desirable pH supporting sperm survival and subsequent fertilization. Stromal-
epithelial interactions play a role in prostate development, tissue homeostasis, 
and later in life contribute to prostate tumorigenesis as discussed within the 
following topics (Bhowmick and Moses 2005).  
 
Androgen Dependence of the Prostate 
 
The prostate is an androgen dependent organ, thus androgens regulate 
proper prostate growth, development, and maintenance (Cunha, Hayward et al. 
2002; Nantermet, Xu et al. 2004; Sakko, Ricciardelli et al. 2007). The prostate 
develops from an ambisexual organ termed the urogential sinus (UGS). 
Paracrine signals from the surrounding connective tissue termed the urogenital 
mesenchyme (UGM) respond to testicular androgens to induce prostatic 
structures. In the absence of sufficient androgens, female sex organs will be 
generated by default. The UGS will then expand into cords of urogenital 
epithelium (UGE) invading into the surrounding UGM to produce prostatic buds. 
6 
These budding structures elongate and undergo branching morphogenesis with 
hollowing of the epithelial structure to produce prostatic ducts. In humans these 
ducts organize into a solid compact gland divided into zones. Whereas in mice, 
these ducts organize into individual lobes.  
Early studies using testicular-feminized (Tfm) mice showed the necessity 
of androgen receptor (AR) expression in both the stroma and epithelia for 
complete maturation of the prostate during development (He, Kumar et al. 1991). 
In tissue recombinants resulting from epithelia lacking AR combined with wild-
type (WT) stroma expressing AR, the prostate ducts that formed did not fully 
mature and lacked prostate secretions indicative of a mature and functional 
prostate. In addition, tissue recombinants that combined stroma lacking AR and 
WT epithelia resulted in vagina-like tissues, which showed that stromal AR was 
necessary to instruct prostatic duct formation by the epithelia. These studies 
stressed the importance of androgen signaling in prostate development.  
More recent studies have shown how androgens regulate many pathways 
thought to be involved not only in development, but also in cancer. In one study, 
primary cultured rat epithelial cells were treated with the synthetic androgen, 
R1881, and analyzed for genes regulated by androgens (Asirvatham, Schmidt et 
al. 2006). They found that androgen regulated genes included those associated 
with differentiation, proliferation, and apoptosis. Interestingly, they also found 
genes associated with inflammatory and immune response pathways including 
the interleukin gene, IL-6. IL-6 is often associated with castrate resistant prostate 
cancer (Dossus, Kaaks et al. 2010). Another study looked at the role of stromal 
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androgens on normal and malignant prostate epithelial growth. When using the 
stroma from Tfm mice, which lack AR expression in the stroma, normal adult 
prostate epithelial cells failed to grow (Gao, Arnold et al. 2001). When malignant 
prostatic epithelial cells- including human PC-82, human LNCaP, human LAPC-
4, and rat R3327G cells- were used combined with Tfm stroma these epithelial 
cells grew in response to androgens. This suggests that normal prostate 
epithelial cells require stromal paracrine androgen signaling for growth; however 
malignant epithelia developed the ability to respond to autocrine androgen 
signaling instead. Further information on altered androgen signaling is discussed 
within the mechanisms for castrate resistant prostate cancer development. 
 
Prostate Cancer Statistics, Diagnosis, and Current Therapies 
 
Among those cancers that have had great strides towards its 
understanding, prostate cancer is still the number one diagnosed cancer and the 
second in cancer deaths among aging American men (Ho, Boileau et al. 2004; 
Arap, Trepel et al. 2008; ACS 2010). When diagnosed early, the five year 
survival rate is nearly 100%. Diagnosis at late stages of progression, however, 
drops the five year survival rate to a mere 34%. It was estimated that in 2010 
there would be 217,730 cases diagnosed, and 32,050 deaths from prostate 
cancer in the United States (NCI 2010).  
Cancer detection and diagnosis have improved dramatically over the last 
few decades (Arap, Trepel et al. 2008). One of the greatest advances in the field 
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of prostate cancer has been the introduction of blood test screening for PSA. Low 
circulating levels of PSA, on average less than 4 ng/mL, are thought to be normal 
and anything higher is carefully monitored (ACS 2010). A significant increase 
over basal levels is also a sign of cancer. This screening test is often used in 
conjunction with the digital rectal exam for tactile detection of cancer. Potential 
tumors are verified with prostate ultrasound and biopsy. Upon diagnosis, there 
are many treatment options and the course of action is determined by the 
physician in accordance with individual patient circumstances.  
Prostate cancer is a slow growing cancer and takes many years to 
develop (Figure 3) (Abate-Shen and Shen 2000). As depicted, prostate cancer 
progresses from normal epithelium to prostatic intraepithelial neoplasia (PIN), 
invasive carcinoma, and finally metastasis. Early stage prostate cancer is usually 
androgen dependent. At this stage the cancer can be effectively treated through 
a prostatectomy or radiation therapy. If surgery or radiation is not a treatment 
option, then androgen ablation therapy may be used. Drugs to block androgen 
signaling impede growth of the prostate and the resulting cancer. The prostate 
regresses as a result and cancer progression is halted. For older men diagnosed 
with prostate cancer, it may not be pertinent to treat it aggressively with surgical 
methods or radiation therapy. Active surveillance is often used if a man is too old 
to risk surgery or the potential side effects from therapy outweigh the benefits of 
treatment. For younger men, prostate cancer is a greater concern since there is a 
greater likelihood for the development of aggressive disease, which will ultimately 
lead to the development of bone metastatic disease. Prostate cancer  
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Figure 3. Pathway for human prostate cancer progression. The stages of 
progression are shown. Loss of glandular architecture and changes in androgen 
status associated with each stage are indicated in red. Loss of specific 
chromosome region and tumor suppressor genes associated with progression 
are shown in dark blue. Image taken from (Abate-Shen and Shen 2000). 
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preferentially metastasizes to the bone (Mundy 2002; Pienta, Abate-Shen et al. 
2008). Currently there are no curative therapies for castrate resistant prostate 
cancer or metastatic disease. Palliative therapies are the only available options 
for castrate resistant disease.   
 
Castrate Resistant Prostate Cancer 
 
The development of castrate resistant prostate cancer (CRPC) is 
accompanied by regrowth of the cancer in addition to metastatic dissemination. A 
significant proportion of the morbidity associated with prostate cancer occurs at 
this late stage of progression. CRPC can arise from multiple mechanisms. The 
prevailing hypothesis suggests that CRPC arises from the primary tumor through 
selective pressure to enable the more aggressive cancer cells to survive in 
diminished or depleted androgen levels. The mechanisms thought to lead to the 
development of CRPC can be classified into five main categories according to 
Feldman and Feldman: 1) hypersensitive AR, 2) promiscuous AR, 3) outlaw AR, 
4) bypass AR, and 5) lurker cells (Figure 4) (Feldman and Feldman 2001).  
 
1) Hypersensitive AR is when the cancer cells adapt by being able to 
respond to very low levels of androgens. Amplification of the androgen receptor 
will better allow the cancer cell to sense and respond to the low amounts of 
androgen available (van der Poel 2005). These cells that are able to respond to 
the low androgen concentration will be selected for with their ability to survive in  
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Figure 4. Five possible pathways to androgen independence. a). 
Hypersensitive pathway. More AR is produced, or has enhanced sensitivity (not 
shown) to compensate for low levels of androgen or more testosterone is 
converted to DHT by 5-reductase. b). Promiscuous pathway. The specificity of 
AR is broadened so it can be activated by non-androgenic molecules normally 
present in the circulation. c). Outlaw pathway. Receptor tyrosine kinases (RTKs) 
are activated and AR is phosphorylated by AKT/PKB or the MAPK pathway to 
produce a ligand-independent AR. d). Bypass pathway. Parallel survival 
pathways such as BCL2 obviate the need for AR or its ligand. e). Lurker cell 
pathway. Castrate resistant cancer cells that are present all the time in the 
prostate- possibly epithelial stem cells- might be selected for by therapy. Figure 
taken from (Feldman and Feldman 2001). 
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the depleted levels. In vitro studies have shown that patient tumor cells with AR 
amplification could withstand androgen ablation longer than the cells devoid of 
amplification (Koivisto, Kononen et al. 1997). 
 Hypersensitivity can be achieved at the transcriptional level. The amount 
of 5-dihydrotestosterone (DHT) needed to stimulate growth in castrate resistant 
cells was four orders of magnitude lower than that necessary for stimulation in 
androgen-dependent cells (Gregory, Johnson et al. 2001). This study showed 
that in models classified as castrate resistant, there can still be proliferation 
resulting from AR transcriptional activity in low androgen concentrations. 
 In addition, hypersensitivity can be a result of increased local production of 
androgens. This local increase is a compensatory mechanism to make up for the 
lower levels of total circulating androgens. Intracrine steroidogenesis allowed 
tumors and metastases to survive in low circulating androgen levels 
(Montgomery, Mostaghel et al. 2008). This may be due to enhanced 5-
reductase activity, which converts the circulating testosterone (TST) into DHT 
within the prostate. This would explain the discrepancy observed that after 
androgen ablation therapy total serum testosterone levels decrease by 95%, 
however, DHT concentration in the prostate has a reduction by only 60% 
(Makridakis, Ross et al. 1997). Also of interest is the correlation of high 5-
reductase activity, notably higher in African American men compared to 
Caucasian men, with increased prostate cancer incidence (Ruijter, van de Kaa et 
al. 1999). This was found to be due to a 5-reductase polymorphism, V89L, 
within the enzyme resulting in higher enzymatic activity.  
13 
 2) The second main category for the development of CRPC is androgen 
receptor promiscuity. This is when non-androgen or androgen antagonists are 
able to bind the androgen receptor to activate signaling. This may be a result of 
AR mutations. In various studies, it has been shown that the frequency of AR 
mutations was higher following androgen ablation therapy compared to the 
primary tumor before therapy (Taplin, Bubley et al. 1995; Tilley, Buchanan et al. 
1996; Marcelli, Ittmann et al. 2000). LNCaP cells were found to have a missense 
mutation in the AR at amino acid 868, T868A, in the ligand binding domain 
(Veldscholte, Berrevoets et al. 1992). This allowed other steroid hormones and 
the androgen antagonist flutamide to bind in its place and activate signaling. 
Other studies have also found missense mutations, including T877A, in the AR 
ligand binding domain that seem to have a selective advantage in metastatic 
growth (Gaddipati, McLeod et al. 1994). 25% of patient tumor samples were 
shown to have the T877A mutation suggesting that it is common in CRPC. Five 
out of 16 patients treated with flutamide were found to have bone marrow 
metastases with AR T877A mutations (Taplin, Bubley et al. 1999). This 
suggested that the treatment selected for cells that could grow in response to 
flutamide. Patients not treated with flutamide were shown to have other 
mutations not associated with flutamide treatment. 
Co-regulators can also alter receptor promiscuity. Steroid hormone 
receptors work with co-activators and co-repressors to activate or repress 
transcription (Shang, Myers et al. 2002; Litvinov, De Marzo et al. 2003; Heitzer 
and DeFranco 2006; Cano, Godoy et al. 2007; Lee, Kim et al. 2008). It has been 
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shown that over-expression of AR co-activators, SRC1 and TIF2, can combine 
with ARs harboring ligand binding domain mutations and enhance the misguided 
signaling (Gregory, He et al. 2001). It was suggested that most patients with 
CRPC have an over-expression of co-activators to allow signaling in low 
androgen levels. Another study showed that lentiviral-AR transduced PC3 cells 
resulted in growth inhibition (Litvinov, Antony et al. 2006). This was accompanied 
by increased p21 and p27 expression upon synthetic androgen R1881 treatment. 
This study emphasized that PC3 cells retain the co-regulators required for the 
tumor suppressor ability of AR, but without a functional AR this suppression is 
lost. 
 
3) The third process for the development of CRPC is the outlaw pathway. 
Outlaw receptors are steroid hormone receptors that can be activated by ligand-
independent mechanisms. It has been shown that growth factors including IGF-1, 
KGF, and EGF can activate the AR (Culig, Hobisch et al. 1994). In LNCaP cells, 
IGF-1 was shown to activate AR signaling greater than the other growth factors 
inducing a five-fold increase in PSA secretion. Furthermore, over-expression of 
these growth factors in prostate cancer suggests that this contributes to the 
development of CRPC. It has also been shown that HER-2/neu is frequently 
over-expressed in CRPC (Craft, Shostak et al. 1999). Androgen-dependent cell 
lines can also be converted to the castrate resistant phenotype by over-
expressing HER-2/neu. This causes activation of AR-dependent genes in the 
absence of DHT. Furthermore, when cells were treated with the AR antagonist 
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bicalutamide, there was no alteration in AR signaling resulting from HER-2/neu 
activation showing that this took place independent of the ligand binding domain. 
It has been shown that HER-2/neu can activate the PI3K/AKT pathway and 
thereby lead to the phosphorylation of AR (Zhou, Hu et al. 2000). In addition, 
dominant-negative AKT blocked the activation of AR mediated through HER-
2/neu (Wen, Hu et al. 2000). Studies have also shown the importance of GSK-3 
and PTEN in CRPC when targeting therapies to PI3K/AKT signaling (Mulholland, 
Dedhar et al. 2006). The loss of PTEN correlates with activation of AKT, which 
can then lead to phospho-inhibition of GSK-3 and subsequent inactivation of 
apoptotic factors. PTEN was suggested as a “gatekeeper” of progressive 
prostate cancer. The frequency of mutations and deletions of PTEN in prostate 
cancer was found to be 60% (Vlietstra, van Alewijk et al. 1998). These studies 
emphasized that alterations in many signaling pathways can ultimately lead to 
the development of CRPC. 
 
4) The fourth mechanism thought to lead to CRPC is the bypass pathway. 
Androgen signaling activation causes cancer cell proliferation. However, there 
are alternative ways to cause cancer cell proliferation and growth without AR. 
BCL2, which blocks apoptosis, has been shown to be expressed in CRPC cells. 
It is not normally expressed in benign prostate epithelial cells. One study 
indicated that tumors grown in castrated mice selected for cells expressing BCL2 
to bypass apoptotic signals (Liu, Corey et al. 1996). Further support comes from 
another model using LNCaP xenografts with antisense oligonucleotides that 
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delayed the progression to CRPC tumors (Gleave, Tolcher et al. 1999). These 
models showed how BCL2 is able to overcome the normal signals for apoptosis 
and allow carcinoma cells to sustain growth. In human CRPC tumors, BCL-2 was 
over-expressed in 62% of locally invasive prostate cancers and 100% of 
metastases after androgen ablation therapy (Colombel, Symmans et al. 1993). 
 
5) The fifth route that may lead to CRPC is the lurker cell pathway. 
Prostate epithelial stem cells are thought to be androgen-independent. When 
prostate stem cells become cancer stem cells, they are not affected by androgen 
ablation and will continue to proliferate. These cancer stem cells give rise to 
androgen-dependent daughter cells comprising the bulk of primary tumors, which 
would be eliminated with androgen ablation therapy.  Androgen ablation therapy 
would act as a selective pressure to allow the androgen-independent cancer 
stem cells to remain, and this leads to CRPC recurrence (Isaacs 1999). A study 
indicated that androgen-independent cells are present in the prostate at a 
frequency of 1 per every 105 -106 androgen-dependent cells (Craft, Chhor et al. 
1999). Prostate cancers are known to be heterogeneous. Similarly, androgen 
status within the cancer cells of primary tumors is also heterogeneous. As most 
advanced prostate cancers are comprised of clonal outgrowths of castrate 
resistant cells, it is likely that these more aggressive cells resulted from selective 
pressure. 
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 Collectively these five mechanisms demonstrate varied approaches a 
cancer cell may adapt to survive in response to androgen ablation. Undoubtedly, 
new mechanisms to develop CRPC will be discovered as our understanding 
increases. It is also likely that combinations of these mechanisms will be used to 
enable enhanced survival in a single cancer cell. These mechanisms to evade 
androgen ablation therapy suggest the need for multimodality therapeutic 
approaches that can target both castrate dependent and resistant cells. These 
five mechanisms are similar with respect to evading androgen ablation, but to 
understand the unique differences will help in tailoring therapies to target specific 
subsets of cancer cells. Each patient has a unique tumor profile, thus efficient 
therapy must be tailored to these differences. 
 
Prostatic Stroma 
 
 The stroma is commonly thought to be a layer of supportive connective 
tissue cells. Prostate stroma is composed of both resident stromal cell types such 
as smooth muscle, fibroblasts, myofibroblasts, fat and vascular cells, as well as 
recruited stromal cell types that include immune cells and other bone marrow 
derived cells (Li, Fan et al. 2007). Paracrine signaling from the stroma to the 
epithelial cells of the prostate is necessary for maintenance of prostate 
homeostasis (Gerdes, Dang et al. 1996; Kurita, Wang et al. 2001; Jackson, 
Franco et al. 2008). Many studies have shown the importance of the stroma in 
preventing or supporting cancer initiation and progression (Cunha, Hayward et al. 
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2002; Tuxhorn, Ayala et al. 2002; Chung, Baseman et al. 2005; Zechmann, 
Woenne et al. 2007; Sung, Hsieh et al. 2008). In contrast, tumor-associated 
stroma plays a role in local cancer growth, invasion, and metastasis. 
 Within the tumor microenvironment, the stroma has a vital role in cancer 
progression. Studies have shown that tumor cells and their associated stroma 
co-evolve (Li, Fan et al. 2007; Polyak, Haviv et al. 2009). It was thought for many 
years that cancer is initiated only in the epithelia. However, studies have since 
demonstrated that the stroma can transform adjacent epithelia through paracrine 
signaling (Bhowmick, Chytil et al. 2004; Kuperwasser, Chavarria et al. 2004). 
Growth factors and chemokines produced by stromal cells enhance epithelial 
growth and transformation. Cancer cells have the ability to undergo morphologic 
transitions influenced by their microenvironment. Epithelial to mesenchymal 
transition (EMT) as well as osteomimicry is thought to enhance the ability of 
carcinoma cells to evade the primary tumor (Thiery 2002). EMT provides cells 
enhanced motility and invasive properties to escape the primary tumor and enter 
circulation (Hay 1995; Condeelis and Segall 2003). Osteomimicry by the cancer 
cells, characterized by expression of genes generally restricted to cells within the 
bone, is thought to result from interaction with the resident prostate stroma in 
preparation for its dissemination to survive in the bone (Koeneman, Yeung et al. 
1999). This shows that the stroma can be a powerful mediator of both tumor 
initiation and tumor progression. 
 Metastasis of cancer cells is influenced by the stroma. Stromal cells 
enhance metastatic events through paracrine signaling to carcinoma cells. A 
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study showed that tumor cells recruited hematopoietic bone marrow-derived cells 
in a VEGF-R1 dependent mechanism (Kaplan, Riba et al. 2005). These recruited 
stromal cells were responsible for creating a pre-metastatic niche for tumor cells. 
Importantly, this showed that expression of VEGF-R1 is responsible for bone 
marrow-derived cell recruitment to primary tumors as well as determining organ-
specific tumor metastases. Moreover, the metastatic potential of LNCaP cells 
was enhanced in a 3-D co-culture system with prostate stromal cells and in 
subcutaneous xenografts (Thalmann, Anezinis et al. 1994; Thalmann, Rhee et al. 
2009). Another study demonstrated the ability of prostate cancer cells to 
metastasize to bone using the SDF-1/CXCR4 signaling pathway (Taichman, 
Cooper et al. 2002). Cancer cells were shown to express varying levels of 
CXCR4 and migrate in response to SDF-1, which is normally produced by 
osteoblasts and endothelial cells. In addition, SDF-1 treatment enhanced cancer 
cell adhesion to endothelial cell lines and osteosarcomas.  
 Therapies to target the stroma in addition to the cancer epithelial cells will 
be more efficacious. An effective study that targeted the stroma used non-
steroidal anti-inflammatory drugs (NSAIDs) to decrease inflammation associated 
with the cancer microenvironment (Sandler, Halabi et al. 2003). Decreased 
inflammation associated with the cancer will decrease the amount of cells 
recruited to the tumor microenvironment. In particular, tumor-associated 
macrophages and neutrophils have been shown to contribute to tumor 
progression by contributing growth factors aiding vasculogenesis (Serafini, De 
Santo et al. 2004; Yang, DeBusk et al. 2004). A study on castrate resistant 
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prostate cancer demonstrated that androgen ablation resulted in the infiltration of 
leukocytes, including B cells, with IKK- activation (Ammirante, Luo et al. 2010). 
This led to enhanced chemokine production that activates IKK- and Stat3 in 
prostate cancer cells. It has also been shown that nuclear cytokine-activated IKK-
 controls prostate cancer metastasis through the tumor suppressor, Maspin 
(Luo, Tan et al. 2007). In addition, reduced Maspin expression in prostate 
epithelial cells correlates with decreased infiltration of RANKL-expression 
inflammatory cells. These stromal components contribute to tumor progression. 
Effective therapies will need to target multiple cell types to eradicate existing 
tumors as well as prevent recurrence or formation of new tumors (Loeffler, 
Kruger et al. 2006). 
 
Transforming Growth Factor- 
 
TGF- signaling is a master regulatory pathway that functions in almost 
every cell. TGF- signaling is important for many processes including 
maintenance of slow cycling cell turn-over, regulating differentiation, maintaining 
the stem cell niche, immune surveillance, extracellular matrix formation, cellular 
morphogenesis, migration, bone remodeling, fibrosis, angiogenesis, and wound 
healing (Massague 1990; Border and Ruoslahti 1992; Sporn and Roberts 1992; 
Wahl 1992; Kulkarni, Huh et al. 1993; Salm, Burger et al. 2005).The activation of 
this pathway begins when the TGF- ligand binds the TGF- type II receptor 
(TRII), which subsequently recruits the TGF- type I receptor (Figure 5)  
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Figure 5. Signaling pathways induced by TGF- receptors. The ligand-
activated type I and II receptor complex recruits and phosphorylates the receptor-
specific Smad2/3 which then recruit Smad4. Transcriptional responses induced 
by the Smad complex have been demonstrated to be associated with ligand-
induced inhibition of cell proliferation, apoptosis, and genomic stability. The 
molecular mechanisms by which TGF activates non-canonical Smad pathways 
such as PI3K/AKT, Rho/Rac GTPases, and Ras/MAPK are less clear. Figure 
taken from (Biswas, Criswell et al. 2006). 
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(Biswas, Criswell et al. 2006). This causes phosphorylation of the receptor Smad 
proteins, Smad2 and Smad3, which can then bind Smad4. These Smad 
complexes then translocate to the nucleus and activate the canonical TGF- 
signaling pathway. TGF- can also activate non-canonical pathways involving 
ERK, p38, and c-Jun N-terminal kinase (JNK). Activation of various genes at the 
transcriptional level occurs in a cell-specific manner through interaction of these 
factors with other transcription factors and co-factors at the level of the genomic 
DNA (Derynck and Zhang 2003; Elliott and Blobe 2005). 
Inflammation is regulated by TGF- signaling. Mice lacking TGF-1 
resulted in extensive autoimmune inflammation affecting many organs (Shull, 
Ormsby et al. 1992; Kulkarni, Huh et al. 1993).  Similarly, conditional knockout 
mice with the TRII gene disrupted after induction with interferon- or 
polyl:polyC resulted in a lethal inflammatory disease (Leveen, Larsson et al. 
2002). Bone marrow transplantation studies using these mice further confirmed 
that the lethal inflammation was a result of aberrant TGF- signaling within cells 
of the hematopoietic lineage. Other cells of the immune system require proper 
TGF- signaling demonstrated by mouse conditional knockout mice. The loss of 
Smad4 signaling in T cells resulted in gastrointestinal cancer (Kim, Li et al. 
2006).  In addition, reduced TGF-signaling in T lymphocytes led to expansion of 
CD8+ memory T-cells (Lucas, McNeil et al. 2004). This led to the formation of 
leukemia/lymphoma. TGF- signaling is crucial for proper immune function. 
TGF- signaling has been implicated in the development and progression 
of many cancers (Letterio 2005; Massague 2008). Its importance in biological 
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processes makes it one of the most frequently altered pathways in human cancer 
(Akhurst 2004; Xu and Pasche 2007). Among those studied, TGF- signaling has 
been shown to be altered in prostate, breast, colon, leukemia, lymphoma, lung, 
pancreatic, and skin cancers (Bottinger, Jakubczak et al. 1997; Akhurst and 
Balmain 1999; Holloway, Davis et al. 2003; Tu, Thomas et al. 2003; Wolfraim, 
Fernandez et al. 2004; Cheng, Bhowmick et al. 2005; Kim, Li et al. 2006; Chen, 
Ghosh et al. 2007). 
In the prostate, TGF- plays a role with other signaling pathways to 
maintain growth and differentiation. AR was shown to down-regulate TGF-1 
expression in LNCaP cells (Chipuk, Cornelius et al. 2002). Specifically, AR binds 
Smad3, but not Smad2 nor Smad4. When Smad3 is bound to AR, binding to 
Smad-binding elements is repressed to inhibit transcription. In prostate smooth 
muscle cells, TGF-1 (but not TGF-2) blocked androgen-stimulated proliferation 
and altered AR distribution from the nucleus to the cytoplasm (Gerdes, Dang et 
al. 1998; Gerdes, Larsen et al. 2004). The crosstalk between androgen and TGF-
 signaling affects differentiation of prostate stromal cells. 
 TGF- signaling is known to regulate prostate cancer initiation and 
progression. There is a loss of epithelial and stromal TRII in human prostate 
cancer compared to benign prostate tissues (Guo, Jacobs et al. 1997; Kim, Ahn 
et al. 1998; Li, Placencio et al. 2008). Another study looking at human prostate 
cancer samples and cell lines found lower mRNA and protein expression of TRII 
compared to BPH samples (Zhao, Shiina et al. 2005). Low mRNA and protein 
expression also correlated with increased CpG methylation of the TRII promoter 
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at the Sp1 binding site -140. Interestingly, treatment of prostate cancer cell lines 
with 5-aza-2‟-deoxycytidine restored TRII expression in PC3 cells. Using a 
transgenic mouse with a dominant negative TRII mutant driven by the ventral 
prostate-specific C3(1) promoter, loss of TGF- signaling caused accumulation of 
ventral prostate epithelial cells and a decrease in apoptosis compared to controls 
(Kundu, Kim et al. 2000). Another mouse model with a dominant negative TRII 
mutant in the epithelia in combination with SV40 transformation led to increased 
metastasis (Tu, Thomas et al. 2003). Conditional loss of stromal Tgfbr2 in 
Tgfbr2fspKO mice caused transformation of the adjacent epithelia that led to the 
formation of prostatic intraepithelial neoplasia (PIN) lesions (Bhowmick, Chytil et 
al. 2004). In long-term studies, this also led to the development of 
adenocarcinoma (Bhowmick, Chytil et al. 2004; Li, Placencio et al. 2008). This 
showed the importance of paracrine signaling from the fibromuscular resident 
stroma to the epithelia. Further studies presented in this thesis characterized the 
mechanism of action within this Tgfbr2fspKO mouse model.  
  
Wnts 
 
One of the signaling pathways important in transferring signals from the 
resident stroma to the epithelia is the Wnt signaling pathway. Wnt signaling has 
been shown to be crucial to developmental processes and contributes to cancer 
progression (Polakis 2000; Giles, van Es et al. 2003; Verras and Sun 2006). Wnt 
signaling begins at the receptor (Figure 6) (Hall, Kang et al. 2006). The primary  
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Figure 6. The canonical Wnt signaling pathway. In the absence of Wnt signals 
(shown in the left side of the diagram) cytoplasmic -catenin is sequestered by a 
complex of Axin, APC, and glycogen synthase kinase 3 (GSK3. 
Phosphorylation of GSK3 leads to ubiquitination and the subsequent 
degradation of -catenin. In the presence of Wnt signals (shown in the right side 
of the diagram), Wnt proteins bind at the cell membrane to a co-receptor 
consisting of Frizzled (FZD) and low-density lipoprotein receptor-related protein 
(LRP). This union results in the hyperphosphorylation of disheveled (DSH), which 
blocks the activity of GSK3. Inhibition of GSK activity results in the stabilization 
and accumulation of -catenin. Upon translocation to the nucleus -catenin 
serves as a co-factor for the TCF family of transcription factors. Histone 
acetylases, p300, and CBP act as co-activators of -catenin activity. Figure taken 
from (Hall, Kang et al. 2006). 
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receptors for Wnt signaling are the seven-transmembrane Frizzled proteins. 
These proteins interact with a single transmembrane LDL receptor-related 
protein 5/6 (LRP5/6), which serve as co-receptors (He, Semenov et al. 2004). 
This receptor complex binds the Wnt ligands from the extracellular matrix. 
Individual Wnt ligands activate the canonical or non-canonical signaling 
pathways. The most studied is the canonical pathway, which stabilizes -catenin 
leading to accumulation in the nucleus. -catenin forms a transcription complex 
with members of the TCF/LEF family, which then bind DNA to activate 
transcription of target genes (Eastman and Grosschedl 1999). Non-canonical 
pathways include the planar cell polarity (PCP) pathway or the Ca++ pathway, 
however their involvement in prostate cancer is not well established. 
Interactions between canonical Wnt and androgen signaling implicate their 
cooperation in prostate cancer progression. Studies demonstrate that -catenin 
acts as an AR co-activator (Mulholland, Cheng et al. 2002). Wnt-3a conditioned 
medium enhanced AR-mediated transcription of PSA with and without androgens 
in LNCaP cells (Shibamoto, Higano et al. 1998; Verras, Brown et al. 2004). 
Alternatively, knockdown of AR with shRNA or bicalutamide treatment reduced 
AR-mediated transcription by Wnt-3a conditioned medium.  This suggests that 
Wnt-3a directly acts on AR. Furthermore, Wnt-3a was shown to enhance cell 
proliferation and colony formation in LNCaP cells.   
Direct binding of -catenin with AR was shown to enhance AR 
transcriptional activity in LNCaP cells (Truica, Byers et al. 2000). This has been 
confirmed in numerous other studies including yeast two-hybrid systems, in vitro 
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and in vivo protein binding assays (Mulholland, Cheng et al. 2002; Pawlowski, 
Ertel et al. 2002; Yang, Li et al. 2002). Androgens enhanced this interaction. 
More specifically, this interaction occurred within the ligand binding domain of 
AR. Interestingly, -catenin was shown to have greater binding affinity to AR 
compared to other hormone receptors including estrogen receptor, progesterone 
receptor, and the glucocorticoid receptor. AR enhances the nuclear translocation 
of -catenin in response to androgens, suggesting its role to enhance Wnt 
signaling in the prostate. It has also been shown that reduced E-cadherin 
enhanced AR-mediated transcription by increasing -catenin levels in both the 
cytoplasm and nucleus (Sasaki, Lin et al. 2000). Reduced expression of E-
cadherin was observed in advanced and poorly differentiated prostate cancer 
(Umbas, Schalken et al. 1992; Richmond, Karayiannakis et al. 1997; Luo, 
Lubaroff et al. 1999). Of interest is the low frequency of -catenin mutations in 
prostate cancer with one study showing only 5% of patient samples having a 
mutation in the serine or threonine residues in the NH2-terminus of -catenin 
(Voeller, Truica et al. 1998; Chesire, Ewing et al. 2000; Gerstein, Almeida et al. 
2002). This is the region responsible for the interaction with AR (Yang, Li et al. 
2002). Analysis of castrate resistant prostate cancer tissues showed an increase 
in -catenin mutations in approximately 20-40% of patient samples (Chesire, 
Ewing et al. 2002; de la Taille, Rubin et al. 2003). The low frequency of -catenin 
mutations suggests that more studies are needed to understand how other 
signaling pathways can activate Wnt signaling in prostate cancer progression. 
Collectively, Wnt signaling plays an important role in prostate cancer progression 
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in cooperation with androgen signaling and likely other major regulatory 
pathways.  
 
Wnt Inhibitors 
 
There are known inhibitors to the Wnt signaling pathway. These include 
secreted frizzled-related proteins (SFRPs), Wnt inhibitory factor-1 (Wif-1), and 
Dickkopf (Dkk) (Figure 7) (Truica, Byers et al. 2000; Jones and Jomary 2002; 
Kawano and Kypta 2003 ; Hall, Kang et al. 2006). SFRPs inhibit Wnt signaling by 
binding Wnt ligands or frizzled receptors, Dkk binds to LRP receptors to block 
LRP-Wnt interactions, and Wif-1 binds Wnt ligands to inhibit binding to receptors. 
SFRPs and Wif-1 inhibit canonical and non-canonical Wnt-mediated signaling 
(Hsieh, Kodjabachian et al. 1999). Dkk only inhibits canonical Wnt signaling (Zorn 
2001). They are expressed in distinct and overlapping patterns depending on the 
cell and tissue (Leimeister, Bach et al. 1998; Terry, Magan et al. 2000). They are 
often expressed in a complementary pattern to individual Wnt ligands (Jaspard, 
Couffinhal et al. 2000). In the prostate, Wnt-3a is often associated with cancer 
progression (Verras, Brown et al. 2004). SFRP-2 has been shown to inhibit Wnt-
3a mediated signaling (Galli, Barnes et al. 2006). Understanding the role of Wnt 
inhibitors may advance treatment options for prostate cancer.  
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Figure 7. Endogenous inhibitors of Wnt signaling. Soluble Frizzled related 
proteins (SFRPs) can sequester Wnts so that they cannot bind to cell surface 
Frizzled (FZD) receptors. Kremen facilitates the binding of Dickkopf (DKK) to the 
Low-density lipoprotein receptor-related protein (LRP), which results in blocking 
Wnt from binding LRP. Wif-1 (not shown) is bound to the cell membrane, but acts 
similar to SFRP by sequestering Wnt ligands inhibiting their binding to receptors. 
Figure taken from (Hall, Kang et al. 2006). 
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Bone Marrow Derived Cells 
 
Bone marrow derived cells (BMDCs) have been shown to play a role in 
cancer progression (Avital, Moreira et al. 2007; Guest, Ilic et al. 2009). They are 
composed of many cell types. The two main progenitor cell types are the 
hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs). HSCs 
are known to differentiate into various cell types including endothelial cells and 
monocytes. MSCs are known to differentiate into many other cell types including 
pericytes and fibroblasts (Roorda, ter Elst et al. 2009). BMDCs have been shown 
to home to various tissues under basal conditions (Krause, Theise et al. 2001). 
However, when inflammation is present in the tissues recruitment of BMDCs is 
enhanced (Li, Stoicov et al. 2006). BMDCs are important for tissue repair to 
enhance subsequent cell and tissue growth through paracrine signaling or 
angiogenic responses. They are also important for removing dead cells or debri 
to restore homeostasis (Roorda, ter Elst et al. 2009).  
Alternatively, BMDCs play a role in tumor progression and it is thought 
that the capacity for self-renewal, longevity, chemoresistance, and susceptibility 
to mutations make these potential cancer stem cells (Liu, Chen et al. 2006; 
Avital, Moreira et al. 2007). BMDCs are known to be recruited to the stroma. 
Tumor stromal cells have been shown to be recruited from progenitor cells in the 
bone marrow (Lyden, Hattori et al. 2001; Rajantie, Ilmonen et al. 2004; De 
Palma, Venneri et al. 2005; Peters, Diaz et al. 2005; Sangai, Ishii et al. 
2005).These bone marrow-derived progenitor cells are mobilized into the 
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circulation, migrate to tumors, and incorporate into the tumor microenvironment 
to enhance growth (Asahara, Murohara et al. 1997; Hattori, Dias et al. 2001; 
Yamaguchi, Kusano et al. 2003; Kawada, Fujita et al. 2004; Ramasamy, Lam et 
al. 2007). The exact role of BMDCs is variable depending on the tissue they are 
recruited to. 
Inflammation in a wound healing response or cancer is known to recruit 
BMDCs (Alison, Lim et al. 2009). One example is the gastrointestinal tract. 
Chronic inflammation is associated with cancer development (Spaeth, Klopp et 
al. 2008). Inflammation serves to recruit BMDCs from the circulation. These cells 
can then incorporate into the associated stroma and contribute by enhancing the 
production of cytokines and induce blood vessel growth (Roorda, ter Elst et al. 
2009). In this milieu, inflammatory cells, including those derived from the bone 
marrow, produce highly reactive oxygen and nitrogen species that can interact 
with cellular DNA to induce mutations (Li, Stoicov et al. 2006). The normal cell 
response to DNA mutations may be to undergo apoptosis. However, in a chronic 
inflammatory environment the chances to bypass apoptosis are favorable and 
growth is allowed to continue (Li, Stoicov et al. 2006). These mutated cells 
continue to divide accumulating further genetic defects leading to the 
development of cancer cells. In a model of gastric cancer induced with 
helicobacter, BMDCs were recruited in this model of chronic inflammation leading 
to cancer development (Houghton, Stoicov et al. 2004). These BMDCs 
incorporated into the prostate epithelial cells through fusion and played a role in 
the progression through metaplasia, dysplasia, and eventually intraepithelial 
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cancer. BMDCs secrete cytokines and growth factors to promote blood vessel 
formation and support stem cell niches to enable cancer development in the 
affected tissue. Other studies have shown that BMDCs are recruited to and 
incorporate into resulting epithelial tissues found in lung, liver, skin, heart, and 
gastrointestinal tract (Krause, Theise et al. 2001; Kawada, Fujita et al. 2004; Li, 
Stoicov et al. 2006). Few studies have examined the recruitment of BMDCS in 
benign and malignant prostate in normal and cancer tissues (Palapattu, Meeker 
et al. 2006; Luo, Tan et al. 2007; Ammirante, Luo et al. 2010). These studies 
suggest multiple BMDC types could contribute to cancer progression, including 
macrophage and B cells. Further studies are needed to understand how BMDCs 
play a role in prostate cancer progression, in particular the progression to 
castrate resistant disease. 
 
Mesenchymal Stem Cells 
 
One sub-population of BMDCs include MSCs. They are classified as a 
non-hematopoietic adult stem cell thought to have properties of a mesenchymal 
lineage. They can be isolated from multiple tissues, but are most commonly 
isolated from the bone marrow. Like most other stromal cell types, they are 
heterogeneous in nature and thus their characterization is not well defined. They 
are able to differentiate into a multitude of cell lineages including osteocytes, 
chondrocytes, adipocytes, stromal cells, and muscle cells. MSCs are routinely 
isolated and expanded in culture (Phinney, Kopen et al. 1999; Short, Brouard et 
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al. 2001). They are characterized as an adherent cell population expressing, 
though disputable, stem cell markers including CD44 and stromal cell markers 
CD90 and CD105 while lacking hematopoietic markers such as CD34 and CD45. 
Studies have shown their ability to home to sites of tissue or organ damage, 
inflammatory microenvironments, and cancer (Spaeth, Klopp et al. 2008). These 
recruited MSCs have been shown to promote tumor growth through expression 
of growth factors, enhance tumor vessel growth, and create tumor stem cell 
niches (Roorda, ter Elst et al. 2009). 
Therapeutic uses with MSCs are of high interest. Pre-clinical studies have 
begun to explore the possibilities of MSCs for therapeutic use. These have been 
used to reduce graft-versus-host disease, tissue repair of cerebral injury, bone 
fractures, myocardial ischemia/infarction and muscular dystrophy (Niedzwiedzki, 
Dabrowski et al. 1993; Li, Chen et al. 2001; Kawada, Fujita et al. 2004; Dezawa, 
Ishikawa et al. 2005). They have been shown to home preferentially to tumor 
stroma as opposed to normal organ stroma in mouse studies (Roni, Habeler et 
al. 2003; Karnoub, Dash et al. 2007). Their migration is induced by growth factors 
or cytokines secreted from the tumor microenvironment. MSCs possess 
chemotactic properties similar to inflammatory cells that enable their recruitment 
to sites of inflammation or tissue remodeling. MSCs express a multitude of 
growth factor, chemokine/ cytokine, adhesion and innate immune surveillance 
receptors (Table 1) (Spaeth, Klopp et al. 2008). These receptors are also 
expressed on inflammatory cells commonly found in tumor microenvironments. 
This suggests that MSCs home and become recruited to the tumor  
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Table 1. Cell surface markers and receptors associated with cell migration 
that are known to be expressed on MSCs. The known ligands for each 
receptor are listed in the third column. The various cell types expressing the 
same receptors are listed in the fourth column. Table taken from (Spaeth, Klopp 
et al. 2008). 
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microenvironment. Studies have also shown that MSCs can be used as vehicles 
for targeted delivery in tumor cells.  One study forced expression of IFN- in 
MSCs (Studeny, Marini et al. 2002). Upon homing to tumor cells, the IFN- 
produced by the MSCs caused inhibition of growth. Another study showed that 
preconditioning MSCs with IGF-1 increased the expression of CXCR4 on the cell 
surface of MSCs allowing them enhanced migration to SDF-1 (Li, Yu et al. 2007). 
Using this information, future trials can use preconditioned MSCs to express a 
plethora of receptors to more efficiently home to certain tumor 
microenvironments versus others. Forced over-expression of receptors in MSCs 
can also be a valuable tool for more specific expression. Targeting MSCs for 
delivery of anticancer drugs and treatments to the tumor microenvironment holds 
promise with a further understanding of these complex cells.  
 
Summary and Dissertation Goals 
 
 Our current understanding of castrate resistant prostate cancer is in its 
early stages. The Nobel Prize discovery that prostate cancer was responsive to 
castration was realized 69 years ago by Huggins and Hogdes (Huggins and 
Hodges 1972). Since then the PSA blood screening test and multiple 
therapeutics have been developed to treat the primary tumor. It has become 
clear in recent years that current androgen ablation therapy, although effective 
initially, results in subsequently enhancing the aggressiveness and castrate 
resistance of the recurrent cancer. The goal of this thesis was to enhance our 
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understanding of CRPC. These studies focused on understanding the role of the 
tumor microenvironment on prostate cancer progression. Paracrine signaling 
from the resident and recruited stroma to the epithelia is discussed in the 
following chapters.  
 
Stromal TGF- signaling mediates prostatic response to androgen ablation by 
paracrine Wnt activity  
These studies were based on our previously developed conditional 
stromal TGF- type II receptor knockout mouse model (Tgfbr2fspKO). Within this 
thesis work, prostates were characterized as castrate resistant providing a novel 
transgenic model to understand CRPC. We demonstrated the involvement of 
paracrine TGF-, androgen, and Wnt signaling in castrate resistance. These 
studies are based on understanding paracrine signaling originating in the 
resident prostate stroma during prostate cancer progression. 
 
Bone marrow derived mesenchymal stem cells incorporate into the prostate 
during regrowth 
Regrowth of the prostate with respect to recruitment of stromal cells was 
studied to understand this aspect of CRPC. We began by examining the 
collective population of BMDCs recruited to the prostate during regrowth. We 
determined that a small population of these total BMDCs, MSCs, were not only 
recruited, but also fused to prostatic ductal epithelia. These MSCs were shown to 
enhance Wnt signaling within castrate resistant tumor epithelia. This study 
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serves as a foundation for future studies on the role of recruited MSCs in the 
prostate cancer microenvironment.  
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CHAPTER II 
 
STROMAL TGF- SIGNALING MEDIATES PROSTATIC RESPONSE TO  
ANDROGEN ABLATION BY PARACRINE WNT ACTIVITY 
 
Introduction 
 Prostate cancer continues to be a major cause of death in aging men 
(Jemal, Tiwari et al. 2004). The prostate is an androgen-dependent organ. As a 
result, treatment for prostate cancer includes the inhibition of androgens. 
Regardless of the initial positive response to androgen ablation, the cancer 
frequently overcomes its dependence on androgens and results in a drug-
resistant cancer with few options for treatment. Although androgen ablation 
therapy is intended to target the prostate epithelia, the influence of the prostatic 
stroma on androgen responsiveness of the adjacent epithelia is likely to be 
critical in the long-term effectiveness of treatment.  
 Mature and differentiated prostate tissue is formed and maintained by 
effects on androgen receptors within the stromal compartment (Cunha and 
Chung 1981; Cunha and Donjacour 1989). The concept of mesenchymal cells 
relaying androgen sensitivity to the epithelia through paracrine interactions is 
supported by tissue recombination experiments. Prostate epithelia expressing a 
non-functional androgen receptor were equally sensitive to androgen ablation, 
carried out by castration of host mice, when compared to the control tissue 
recombinations generated with wild type mesenchyme and wild type epithelia 
(Donjacour and Cunha 1993; Kurita, Wang et al. 2001). Yet mesenchymal cells 
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with a non-functional androgen receptor did not even support prostate epithelial 
development (Cunha and Lung 1978). This suggested that the prostatic stroma 
plays an instructive role in glandular development and potentially influences 
responsiveness to androgen ablation in prostate cancer progression (Kurita, 
Wang et al. 2001). As a basis to understanding androgen independent prostate 
cancer, we investigated the mechanism for prostate epithelial survival in the 
absence of androgens.  
 Following androgen ablation the prostate undergoes apoptotic regression. 
In mouse models, reintroduction of androgens following androgen ablation 
results in prostate regrowth originating from the proximal ducts. This observation 
indicates that the proximal ducts are inherently refractory to androgen ablation 
(Lee, Sensibar et al. 1990; Rouleau, Leger et al. 1990; Prins, Cooke et al. 1992). 
Canonical Wnt signaling is known to play a role in cell survival in many tissues 
(Mount, Muzylak et al. 2006; Terry, Yang et al. 2006)Verras, 2006 #120}. Thus, 
we wanted to investigate a potential role for Wnt signaling in the survival of 
proximal ductal tissue upon castration. Another growth factor, TGF-, is thought 
to support prostatic apoptosis as its expression coincides with androgen ablation 
in benign and cancer tissues (Kyprianou and Isaacs 1989; Hsing, Kadomatsu et 
al. 1996; Brodin, ten Dijke et al. 1999). TGF- binds the TGF- type II receptor 
(Tgfbr2) at the cell surface to phosphorylate the TGF- type I receptor and 
activate cytoplasmic proteins, predominantly Smad2 and Smad3 (Massague and 
Gomis 2006). Both cooperative and antagonistic interactions of Wnt, androgen, 
and TGF- signaling pathways occur in the prostatic epithelia (Hayes, Zarnegar 
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et al. 2001; Kang, Lin et al. 2001; Chipuk, Cornelius et al. 2002; Yang, Chen et 
al. 2006). However, the role of Wnt and TGF- signaling on androgen 
dependence of the prostate is unknown.  
We tested the hypothesis that paracrine Wnt signaling regulates stromal-
epithelial interactions in response to androgen ablation in a TGF--dependent 
manner using mouse and allografting models.  Canonical Wnt signaling involves 
the activation of cognate frizzled receptors at the cell surface that mediate -
catenin accumulation leading to transcriptional activity in the nucleus (Widelitz 
2005). Here we report that canonical Wnt activity is present in the prostatic 
epithelia of the proximal ducts of the prostate following androgen ablation. 
Previously, we generated a Tgfbr2 conditional fibroblast knockout mouse through 
FSP-1 Cre-mediated recombination of Tgfbr2 exon 2 (Tgfbr2fspKO), which resulted 
in the development of pre-neoplastic lesions (prostatic intraepithelial neoplasia) 
by five to seven weeks of age (Bhowmick, Chytil et al. 2004). To further study the 
role of TGF- on the prostate epithelia following androgen ablation, here we 
developed a conditional epithelial Tgfbr2 knockout by crossing NKX3.1-Cre mice 
with Tgfbr2floxE2/floxE2 mice (Chytil, Magnuson et al. 2002), termed Tgfbr2NKX3.1KO. 
Another valuable tool was the Tg(Fos-lacZ)34Efu/J mouse model, termed 
TOPGal, enabled the visualization of canonical Wnt signaling activity (DasGupta 
and Fuchs 1999). Interestingly, the prostates of Tgfbr2fspKO mice had constitutive 
Wnt signaling throughout the prostate and were resistant to androgen ablation 
induced regression. The 12T7f LADY mouse model served as a transformed 
epithelial counterpart, expressing SV40 Large T antigen in the prostatic epithelia 
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(Kasper, Sheppard et al. 1998). Tissue recombination allografting of the 
Tgfbr2fspKO prostatic stroma was able to convert the androgen-dependent 12T7f 
LADY prostatic epithelia to become refractile to androgen ablation. Together, the 
data provides a mechanism for androgen independent survival of the prostate 
epithelia. 
 
Materials and Methods 
 
Transgenic Mice 
 
Tgfbr2floxE2/floxE2 (Shappell, Thomas et al. 2004) and Tgfbr2fspKO mice of C57BL/6 
background were generated as previously described (Bhowmick, Chytil et al. 
2004). The NKX3.1-Cre mice, also in the C57BL/6 background, were crossed 
with Tgfbr2floxE2/floxE2 mice to generate the Tgfbr2NKX3.1KO mouse model. The 
Tgfbr2NKX3.1KO mice were further crossed with Rosa26 mice to enable 
visualization of cells undergoing Cre-mediated recombination. TOPGal mice 
(DasGupta and Fuchs 1999) were purchased from Jackson Laboratories and 
crossed with Tgfbr2floxE2/floxE2 and the Tgfbr2floxE2/wt-CreFSP mice to generate the 
Tgfbr2floxE2/floxE2/TOPGal and Tgfbr2fspKO/TOPGal mouse models. Prostatic 
epithelial organoids were generated from 15 week-old 12T7f LADY mice, at 
which time they developed high-grade hyperplastic lesions and foci of 
adenocarcinoma (Kasper, Sheppard et al. 1998; Tuxhorn, Ayala et al. 2002). All 
mice were genotyped from ear punch biopsies. NKX3.1-Cre mice were 
42 
genotyped using the same Cre primers as the Tgfbr2fspKO mice (Bhowmick, Chytil 
et al. 2004). A single approximately 200bp band indicated Cre expression. All 
other mouse genotyping was performed as previously reported (Kasper, 
Sheppard et al. 1998; DasGupta and Fuchs 1999; Shappell, Thomas et al. 2004). 
Harlan Sprague Dawley (Indianapolis, IN) SCID CB17/ICR hsd and C57BL/6 
mice were used for tissue recombination and tissue rescue allografting 
techniques, respectively. All animal procedures were approved by the Vanderbilt 
Institutional Animal Care and Use Committee. 
 
Cell Culture 
 
Tgfbr2floxE2/floxE2 and Tgfbr2fspKO mouse primary prostate stromal cell cultures were 
generated from prostates of 6-8 week old mice, as described previously 
(Roberts, Sporn et al. 1986). Cultures grown between passage ten and thirty 
were used for experiments. LNCaP cells were purchased and grown as 
recommended by ATCC.  
 
Conditioned media experiments and 3H-thymidine Incorporation 
 
Conditioned stromal media was generated by plating 750,000 Tgfbr2floxE2/floxE2 or 
Tgfbr2fspKO cells or for control 3,000,000 LNCaP cells on a 100mm dish similar to 
previously published reports (Bhowmick, Ghiassi et al. 2001). Tgfbr2floxE2/floxE2 and 
Tgfbr2fspKO stromal cells were transduced with either GFP (control) or secreted 
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frizzled related protein-2 (SFRP-2) adenovirus at 105-virus particles/mL for 24 
hours prior to replacing standard stromal cell culture media with the lower serum 
media to allow virus production in stromal cells. The stromal cells were incubated 
for 72 hours in the stromal cell media containing 10-8 M testosterone or if 
indicated, bicalutamide (10-5 M). The stromal conditioned media was transferred 
to 15 mL conical tubes and stored in -80oC at least 24 hours up to three weeks. 
The stromal conditioned media was thawed, and plated over LNCaP cells 
(10,000 cells per well) in 24 well plates. The conditioned media was replaced 
after 72 hours of incubation with fresh conditioned media. In select conditions, 
fresh bicalutamide was also included as part of the conditioned media. Following 
120 hours of incubation of LNCaP cells with stromal conditioned media, 3H-
thymidine incorporation assays were performed. Three hours prior to assaying 
for proliferation, cells were given 2 µCi 3H-thymidine (PerkinElmer, Waltham, MA) 
in serum free RPMI per well. Cells were washed in 1 mL 10% TCA for 10 min, 
three times then lysed with 300 µl 200 mM NaOH for 30 min. The cell lysates 
(100 µl) were measured for 3H-thymidine activity using a scintillation counter 
(Hayward, Haughney et al. 1998). All treatment conditions were performed in 
triplicate. 
 
Immunohistochemistry 
 
Tissues were fixed with 4% paraformaldehyde, embedded in paraffin, and 
sectioned for histological analysis. GFP (1:1000, Santa Cruz, CA), Ki67 (1:3000, 
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Vector Laboratories), and SV40 (1:1000,Calbiochem, SanDiego, CA) 
immunohistochemistry was performed by using antigen retrieval with antigen 
unmasking solution (Vector Laboratories, Burlngame, CA) diluted 1:100. 
Following primary antibody incubation overnight, Dako Cytomation Universal or 
Rabbit kits were used for the secondary antibody and development with DAB. 
TUNEL staining was performed using the ApopTag Peroxidase In Situ Apoptosis 
Detection Kit (Chemicon, Temecula, CA). Double immunohistochemical staining 
was performed for TUNEL followed by staining for ß-galactosidase (1:5000, 
Abcam, Cambridge MA) developed with TrueBlue Peroxidase Substrate (KPL, 
Gaithersburg, MD). Immunohistochemical staining was systematically quantitated 
by taking a ratio of positively stained cells per epithelial nuclei per field (200x). 
Statistical significance was determined by two tailed Student‟s t test. 
 
Immunofluorescence 
 
50,000 cells were treated with 5 ng/ mL TGF- (Cell Sciences, Canton, MA) on 
glass coverslips for 6 hours. The cells were fixed with 4% paraformaldehyde for 
10 min. at 4oC. Smad2 localization was visualized using primary (1:1000, Santa 
Cruz Biotechnology, Santa Cruz, CA) and secondary anti-goat Alexa Fluor 594 
antibody (1:500, Invitrogen. Carlsbad, CA) on a Nikon epifluorescence 
microscope. 
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-galactosidase tissue staining 
 
Whole mouse prostates were dissected and fixed in 4% PFA for one to two 
hours, washed in PBS, incubated with X-gal for 3 hr at 30ºC, washed in PBS, and 
fixed in 4% PFA overnight. Processed paraffin embedded tissues were sectioned 
at 8 µm and counterstained with Nuclear Fast Red (Electron Microscopy 
Sciences, Hatfield, PA). 
 
Tissue recombination allografting 
 
The tissue recombinations were performed as previously described (Strutz, 
Okada et al. 1995). Epithelial organoids were derived by digesting prostates of 6-
12 week old wild type C57BL/6 mice or 15 week- old LADY 12T7f mice in 675 
units/mL collagenase with 0.04% DNAse type I at 37ºC for 40 min as previously 
described (Strutz, Okada et al. 1995). The organoids were washed and pipetted 
into 50 µl collagen with stromal cells from Tgfbr2floxE2/floxE2 or Tgfbr2fspKO mouse 
prostates and allowed to incubate overnight at 37oC. The tissue recombinants 
were then allografted under the renal capsule of syngenic C57BL/6 for 5 to 7 
weeks or SCID mice for 6 weeks. Castration of host mice was performed 3-7 
days prior to sacrifice as indicated.  
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RNA purification and RT-PCR 
 
RNA from cell lysates was purified using the RNeasy mini kit (Qiagen, Valencia, 
CA) according to the manufacturer‟s directions. RT-PCR was performed for 32 
cycles with the following primer sets: Wnt-2 forward 
5‟GTTTGCCCGTGCCTTTGTAGATG reverse 5‟CCGGGTGACGTGGATGTG, 
Wnt-3a forward 5‟TCTGCAGGAACTACGTGGAGATCA reverse 
5‟TCCCGAGAGACCATTCCTCCAAAT, Wnt-5a forward 
5‟TCGCCATGAAGAAGCCCATTGGAA reverse 
5‟TGTCCTTGAGAAAGTCCTGCCAGT, Wnt-9a forward 
5‟ACTGCTTTCCTCTACGCCATCTCT reverse 
5‟TTTGCAAGTGGTTTCCACTCCAGC, Wnt-11 forward 
5‟CTGACATGCGCTGGAACTGCTC reverse 5‟AGGCCCGGGCGATGGTGT, 
and 18S forward 5‟ CAAGAACGAAAGTCGGAGGTTC reverse 
5‟GGACATCTAAGGGCATCACAG.  
 
Results 
 
Stromal TGF- responsiveness enables prostatic regression  
after androgen depletion  
 
Androgen ablation causes prostate regression with a transient elevation of 
TGF- expression (Kyprianou and Isaacs 1989). However, the role of TGF- on 
the prostate following androgen ablation is not clear. We first developed a 
conditional Tgfbr2 knockout targeted to the epithelia by crossing NKX3.1-Cre 
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mice with Tgfbr2floxE2/floxE2 mice, termed Tgfbr2NKX3.1KO (conditional epithelial 
Tgfbr2 knockout). Further crossing the Tgfbr2NKX3.1KO mice into the Rosa26 line 
enabled the immunohistochemical localization of -galactosidase expression 
associated with Cre-mediated recombination in the prostatic epithelia (Figure 
8A). Since the Tgfbr2NKX3.1KO mice died perinatally, the prostates of these and 
Tgfbr2floxE2/floxE2 mice were rescued to the renal capsule of syngenic C57BL/6 
male hosts. Hematoxylin and eosin (H&E) staining revealed little difference in the 
ductal structures of the Tgfbr2NKX3.1KO prostates compared to Tgfbr2floxE2/floxE2 
controls (Figure 8B). However, the Tgfbr2NKX3.1KO prostates had significantly 
higher epithelial turnover as demonstrated by the apoptotic TUNEL staining 
(Figure 8B, lower panels; statistical graph shown in Figure 9) compared to 
Tgfbr2floxE2/floxE2 allografts. Following castration there was a further elevation of 
epithelial TUNEL staining in the Tgfbr2NKX3.1KO prostates as observed in 
Tgfbr2floxE2/floxE2 allografts. Taken together, there was no significant difference in 
apoptotic response observed between Tgfbr2floxE2/floxE2 and Tgfbr2NKX3.1KO 
prostates following castration compared to their intact controls, respectively.  
As epithelial TGF- signaling did not seem to affect androgen 
responsiveness, the role of stromal TGF- signaling was studied using the 
Tgfbr2fspKO mouse model (conditional stromal Tgfbr2 knockout). The castration of 
Tgfbr2floxE2/floxE2 mice resulted in 42% and 55% decrease in the total prostate wet 
weights, after seven and fourteen days, respectively (Figure 10A). In contrast, 
there was a negligible decrease in Tgfbr2fspKO prostates wet weight seven days 
following castration, with approximately 20% regression by fourteen days.  
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Figure 8. Conditional knockout of Tgfbr2 in the prostate epithelia 
(Tgfbr2NKX3.1KO) did not significantly affect the response to androgen 
ablation compared to control Tgfbr2floxE2/floxE2 prostate allografts. (A) 
Immunohistochemistry for -galactosidase expression (brown) in tissue rescued 
Tgfbr2NKX3.1KO/Rosa26 prostates indicates Cre-recombination in the prostatic 
epithelia compared to control, Tgfbr2floxE2/floxE2/Rosa26 prostates with no 
detectible staining.  Sections were counterstained with hematoxylin (blue). The 
epithelial (E) and stromal (S) compartments are indicated. (B) (Upper Panels) 
H&E staining of Tgfbr2NKX3.1KO and Tgfbr2floxE2/floxE2 tissue rescue allografts 
suggest similar prostatic development (n=4). (Lower Panels) TUNEL staining 
(brown) indicates differential apoptosis of the prostatic epithelia of Tgfbr2NKX3.1KO 
and Tgfbr2floxE2/floxE2 allografts in hosts that were not castrated (+Androgen) 
compared to hosts that were castrated (-Androgen). Increased TUNEL positive 
epithelia after castration indicates responsiveness to androgen ablation. The 
increase in TUNEL positive epithelia in intact compared to castrated 
Tgfbr2floxE2/floxE2 prostates was significant (P value = 0.0379). The increase in 
TUNEL positive epithelia in intact compared to castrated Tgfbr2NKX3.1KO prostates 
was significant (P value = 0.0056). Student’s t test evaluation determined P value 
< 0.05 is significant. Figure taken from (Placencio, Sharif-Afshar et al. 2008). 
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Figure 9. Quantitation for figures with TUNEL and Ki67 staining of the 
epithelia in Chapter II. Bar graphs show the average percent positive epithelial 
staining of TUNEL or Ki67 staining. The graph title indicates the corresponding 
figure. The tables of p-values designate a description of the compared values. P-
values <0.05 indicate significance according to Student’s t test analysis. 
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Figure 10. Tgfbr2fspKO prostates lose androgen responsiveness after 
androgen ablation. (A) Percentage change in total wet prostate weight is shown 
seven and fourteen days following castration (Cx). Average Tgfbr2floxE2/floxE2 and 
Tgfbr2fspKO total wet prostate weights are shown as a percentage of the 
respective total prostate weight from intact Tgfbr2floxE2/floxE2 (Flox) and Tgfbr2fspKO 
(KO) mice (n=5). (B) Three days following castration, DL prostate lobes of 
Tgfbr2floxE2/floxE2 and Tgfbr2fspKO mice were subjected to TUNEL staining (brown) 
indicating apoptotic cells and Ki67 staining (brown) indicating proliferative cells. 
Hematoxylin (blue) was used as a nuclear counter stain. The stromal (S) 
compartment is indicated and black arrows indicate positively stained epithelial 
cells. Prostates were dissected from 5-7 week old male mice. Dorsolateral lobes 
are shown and these effects are consistent with all other lobes (n=8). The 
increase in TUNEL positive Tgfbr2fspKO epithelia after castration was significantly 
greater than Tgfbr2floxE2/floxE2 epithelia (P value = 0.0152). The level of Ki67 
positive Tgfbr2fspKO epithelia after castration was significantly greater than 
Tgfbr2floxE2/floxE2 epithelia (P value = 0.0003). Figure taken from (Placencio, 
Sharif-Afshar et al. 2008). 
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Histologic analysis revealed that seven days following castration the 
Tgfbr2floxE2/floxE2 prostates, with otherwise low cellular turnover, had an expected 
increase in TUNEL-positive apoptotic cells in both the epithelial and stromal 
compartments and little evidence of proliferation observed by Ki67 staining 
(Figure 10B). Prior to castration, Tgfbr2fspKO mice exhibited slightly higher rates of 
apoptosis than Tgfbr2floxE2/floxE2 mice (1.4-fold), accompanied by significant 
proliferation consistent with the described PIN phenotype (Bhowmick, Chytil et al. 
2004). Seven days following castration, prostates from Tgfbr2fspKO mice had little 
apparent epithelial apoptosis, yet remained highly proliferative based on TUNEL 
and Ki67 staining, respectively. The apparent elevated proliferation of the 
Tgfbr2fspKO stroma coincided with greater stromal expansion compared to 
Tgfbr2floxE2/floxE2 prostates. Together, these data suggested that normal prostate 
epithelial regression occurs in response to stromal TGF- signals.  
Before further studying the androgen independence of the prostates in 
Tgfbr2fspKO mice, we needed to establish that the epithelial response resulted 
from the prostatic stroma and not other systemic factors in these mice. The FSP-
1 Cre promoter targets a subset of fibroblasts throughout the body, including 
prostatic fibroblasts (Hayward 2002; Bhowmick, Chytil et al. 2004). We verified 
the loss of TGF- responsiveness in Tgfbr2fspKO cultured stromal cells by 
immunolocalization of Smad2 (Figure 11A). A tissue recombination allograft 
approach was then utilized to identify the role of the prostatic stromal cells in the 
phenotype observed. The tissue recombination technique consisted of combining 
cultured stromal cells derived from Tgfbr2floxE2/floxE2 or Tgfbr2fspKO prostates with 
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Figure 11. Loss of TGF- responsiveness in prostatic stromal cells causes 
the prostate to become refractory to androgen ablation. (A) To assess the 
competency of Tgfbr2floxE2/floxE2 and Tgfbr2fspKO prostatic stromal cells for TGF- 
signaling Smad2 was localized by Alexa Fluor 594 (red) immunofluorescence 
staining following TGF- treatment. Hoechst nuclear counter stain was used 
(blue). Colocalization of Smad2 with Hoechst indicates active TGF- signaling, 
whereas disparate staining indicates a lack of TGF- signaling. (B) H&E staining 
of prostatic glandular structures in tissue recombination grafts of Tgfbr2floxE2/floxE2 
and Tgfbr2fspKO stromal cells with epithelial organoids were allografted for six 
weeks in intact (2 upper panels) syngenic host male mice (+ Androgen) (n=8) or 
castrated (2 lower panels) for the last week of grafting in syngenic host male 
mice (- Androgen) (n=8). “Kd” indicates kidney tissue. The black bar indicates 
100uM. (C) TUNEL staining (indicated with black arrows) in Tgfbr2floxE2/floxE2 and 
Tgfbr2fspKO tissue recombination grafts from castrated mice is shown (n=4). The 
level of TUNEL positive Tgfbr2fspKO–associated epithelia after castration was 
significantly lower than Tgfbr2floxE2/floxE2–associated epithelia (P value = 0.0249). 
The black bar indicates 50 uM. (D) Ki67 staining (black arrows) indicate 
proliferative cells of Tgfbr2floxE2/floxE2 and Tgfbr2fspKO allografts from castrated mice 
(n=4).  Open arrowheads indicate background staining of likely dead cells and 
“Kd” indicates kidney tissue. The level of Ki67 positive Tgfbr2fspKO–associated 
epithelia after castration was significantly greater than Tgfbr2floxE2/floxE2–
associated epithelia (P value = 0.0030). The black bar indicates 50 uM. Figure 
taken from (Placencio, Sharif-Afshar et al. 2008). 
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epithelial organoids isolated by digesting mature wild type C57BL/6 mouse 
prostates. The tissue recombinants were allografted to the sub-renal capsules of 
syngeneic male mice (Voeller, Truica et al. 1998). Five weeks following grafting, 
the Tgfbr2floxE2/floxE2 and Tgfbr2fspKO stromal cells organized themselves around 
the epithelial organoids to form prostatic glands (Figure 11B). Seven days 
following castration of the hosts there was a 6-fold increase in TUNEL-positive 
epithelia in the Tgfbr2floxE2/floxE2 stroma-associated glands (Figure 11C). Note, in 
comparison, the Tgfbr2fspKO stroma-associated glands did not show a significant 
increase in TUNEL-positive epithelia. Ki67 staining indicated minimal proliferation 
in recombinants associated with Tgfbr2floxE2/floxE2 stroma following castration 
(Figure 11D). In contrast, the recombinants associated with Tgfbr2fspKO stroma 
had greater epithelial proliferation following castration. Collectively, castration of 
the host mice resulted in regression of the allografted tissue recombinants 
associated with Tgfbr2floxE2/floxE2, but not Tgfbr2fspKO stromal cells. These 
observations further supported that the androgen ablation refractile phenotype of 
our Tgfbr2fspKO mice resulted from interactions within the prostate 
microenvironment. 
 
Proximal ductal epithelial activation of Wnt signaling following androgen ablation 
mediates stromal-epithelial crosstalk 
The next step was to determine how TGF- signaling within the stroma 
was responsible for the observed regression in the Tgfbr2floxE2/floxE2, or lack 
thereof in the Tgfbr2fspKO, mouse prostates. The proximal ducts of the prostate 
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remain viable as the distal ducts regress in the absence of androgen signaling. 
Up-regulation of Wnt ligands and activating mutations of -catenin in prostate 
cancer epithelium is a potential mechanism for androgen refractory prostatic 
epithelial proliferation (Truica, Byers et al. 2000; Chen, Shukeir et al. 2004; Galli, 
Barnes et al. 2006). To address the potential of a Wnt signaling mechanism to 
support the androgen independent prostate survival phenotype observed, we 
developed a Tgfbr2fspKO/TOPGal mouse model (conditional stromal Tgfbr2 
knockout with a canonical Wnt signaling reporter). Intact and castrated male 
Tgfbr2floxE2/floxE2/TOPGal and Tgfbr2fspKO/TOPGal prostates were subjected to 
whole mount -galactosidase staining to visualize canonical Wnt activity. In 
whole mount staining of prostates from intact Tgfbr2floxE2/floxE2/TOPGal mice, -
galactosidase expression was not detected (Figure 12A). However, three days 
after castration -galactosidase activity was detected exclusively in the proximal 
ducts of the prostate indicating activated -catenin signaling. This was further 
supported by elevated immuno-localization for -galactosidase expression in the 
proximal glands of Tgfbr2floxE2/floxE2/TOPGal prostates following castration (Figure 
13). By the seventh day following castration, little -galactosidase activity was 
detected in Tgfbr2floxE2/floxE2/TOPGal prostates (data not shown). In contrast to 
that observed in Tgfbr2floxE2/floxE2/TOPGal prostates, Figure 12A showed that the 
Tgfbr2fspKO/TOPGal prostates had -galactosidase expression in the entire gland 
before castration with further elevated expression following castration. In both 
Tgfbr2floxE2/floxE2/TOPGal and Tgfbr2fspKO/TOPGal prostates, only the epithelial 
compartment showed strong positive -galactosidase activity (Figure 12B, C).  
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Figure 12. Inhibiting TGF- signaling in the prostatic stroma results in 
constitutive Wnt signaling throughout the prostatic epithelia associated 
with survival following androgen ablation. Six week old TOPGal mice were 
stained for -galactosidase activity and anterior and dorsolateral prostate lobes 
from intact and three day castrated mice were analyzed. (A) 
Tgfbr2floxE2/floxE2/TOPGal and Tgfbr2fspKO/TOPGal prostates from intact and three 
days following castration were stained for -galactosidase activity (blue) and 
imaged as whole mounts (n=8) to show areas of canonical Wnt signaling activity. 
(B) Paraffin sections of the -galactosidase stained intact 
Tgfbr2floxE2/floxE2/TOPGal and Tgfbr2fspKO/TOPGal distal prostates were counter 
stained with Nuclear Fast Red. Asterisks indicate the stromal compartment. 
(Prostates from intact and castrated Tgfbr2fspKO/TOPGal mice were similar. Only 
the intact Tgfbr2fspKO/TOPGal tissue section is shown.) (C) Three days after 
castration, paraffin sections of the -galactosidase stained 
Tgfbr2floxE2/floxE2/TOPGal prostate was counter stained with Nuclear Fast Red. 
Tissue section shows the distal prostate as it is regressing toward the proximal 
area. Asterisks indicate the stromal compartment. (D) Following castration of 
control Tgfbr2floxE2/floxE2/TOPGal mice, the -galactosidase activity stained 
prostate sections were co-stained for TUNEL (brown) indicated with black arrows 
and -galactosidase expression (blue) (n=4). Tissue section shows the distal 
prostate as it is regressing toward the proximal area. Asterisks indicate the 
stromal compartment and black arrows indicate the epithelia with no -
galactosidase activity following castration (n = 8). Figure taken from (Placencio, 
Sharif-Afshar et al. 2008). 
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Figure 13. Wnt signal activity in the prostatic proximal ducts. 
Tgfbr2floxE2/floxE2/TOPGal and Tgfbr2fspKO/TOPGal prostates were sectioned and 
stained for -galactosidase using immunohistochemistry. Note, the increase in -
galactosidase staining in the proximal ducts after castration in both the 
Tgfbr2floxE2/floxE2/TOPGal and Tgfbr2fspKO/TOPGal glandular epithelia. Scale bare 
indicates 25 µM. Figure taken from (Placencio, Sharif-Afshar et al. 2008). 
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Co-staining for TUNEL and -galactosidase in Tgfbr2floxE2/floxE2/TOPGal flox 
prostate glands, four days following castration, illustrated that the epithelia 
expressing -galactosidase did not overlap with epithelia undergoing apoptosis 
(Figure 12D). This finding suggested that the epithelia in the proximal glands 
supported canonical Wnt activity during normal prostatic regression following 
androgen ablation. In addition, the hormone refractory Tgfbr2fspKO prostates 
supported constitutive paracrine canonical Wnt signaling. The coincident 
localization of canonical Wnt signaling in Tgfbr2floxE2/floxE2/TOPGal prostates and 
the reported region surviving androgen ablation supported the possibility of a 
causal relationship between the two events.  
To determine if the observed epithelial Wnt activity could be due to 
stromal regulation of Wnt ligand production, Tgfbr2floxE2/floxE2 and Tgfbr2fspKO 
cultured prostatic stromal cells were treated with an androgen receptor 
antagonist, bicalutamide. The expression of Wnt ligands was measured following 
androgen ablation over a time course of five days by semi-quantitative RT-PCR. 
There was a transient increase in Wnt-2, Wnt-3a and Wnt-5a one and three days 
following bicalutamide treatment of Tgfbr2floxE2/floxE2 stromal cells, with a decrease 
in expression by five days (Figure 14A). A similar trend was seen with Tgfbr2fspKO 
stromal cells, but with elevated basal expression for Wnt-2, Wnt-3a and Wnt-5a. 
Wnt-9a and Wnt-11 expression were unchanged in both stromal cell types under 
the same conditions. When Tgfbr2floxE2/floxE2 stromal cells were treated with 
bicalutamide and TGF- there was a lack of Wnt expression compared to 
treatment with bicalutamide alone (data not shown). Thus, inhibiting either the  
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Figure 14. Wnt signaling induced by androgen ablation of stromal cells 
affects epithelial proliferation. (A) Tgfbr2floxE2/floxE2 and Tgfbr2fspKO stromal cells 
were treated with bicalutamide over five days to analyze Wnt gene expression by 
semi-quantitative RT-PCR. The expression of 18S ribosomal RNA was used as a 
loading control. The results shown are representative of three or more sets of 
RNA used to test each Wnt gene. (B) 3H-thymidine incorporation assays were 
performed on Tgfbr2floxE2/floxE2 and Tgfbr2fspKO stromal cells transduced with GFP-
adenovirus and grown either in media containing testosterone or bicalutamide 
(Bic) in the absence of testosterone. 3H-thymidine incorporation assays were 
performed on LNCaP epithelial cells also treated with or without bicalutamide for 
five days. Each bar represents the average of three or more replicates and error 
bars indicate standard deviation. Asterisks indicate significance compared to the 
respective control. GFP- Tgfbr2floxE2/floxE2 stromal cells were not significantly 
affected by bicalutamide treatment compared to control GFP- Tgfbr2floxE2/floxE2 
stromal cells (P value = 0.0580). GFP-Tgfbr2fspKO stromal cells had a significant 
increase in proliferation with bicalutamide treatment compared to control GFP-
Tgfbr2fspKOstromal cells (P value = 0.0016). LNCaP epithelial cells treated with 
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bicalutamide (Bic) proliferated significantly faster than untreated LNCaP cells (P 
value = 0.0025). Data is representative of three or more individual experiments. 
(C) On the left, a cartoon of the generation of conditioned media is shown. 
Conditioned media was collected from Tgfbr2floxE2/floxE2 or Tgfbr2fspKO stromal cells 
and used to treat the target LNCaP epithelial cells. To the right, bar graphs show 
the results of these conditioned media experiments.  Androgen responsive 
proliferation of LNCaP cells was measured in response to a 120 hour treatment 
with conditioned stromal cell media from Tgfbr2floxE2/floxE2 or Tgfbr2fspKO cells by 
3H-thymidine incorporation assays. Tgfbr2floxE2/floxE2 and Tgfbr2fspKO stromal cells 
were transduced either with GFP adenovirus as a control or Wnt antagonist 
SFRP-2 adenovirus prior to starting collection of conditioned media. ‘Bic on Stro’ 
indicates that bicalutamide was added to stromal cell cultures during the 
generation of conditioned media. ‘Bic on Epi’ indicates that bicalutamide was 
added to epithelial LNCaP cells simultaneously with stromal conditioned media 
treatment. Each bar represents the average of three or more replicates and error 
bars indicate standard deviation. Compared to the GFP control, P values for 
SFRP-2- Tgfbr2floxE2/floxE2 conditions are 0.207, 0.339, and 0.011, and for SFRP-
2-Tgfbr2fspKO conditions 0.002, 0.005, and 0.004, respectively. Each asterisk 
indicates statistical significance between the control and knockout data points for 
a given condition with a P value < 0.05 according to a Student’s t test evaluation. 
Figure taken from (Placencio, Sharif-Afshar et al. 2008). 
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androgen or the TGF- signaling pathway could induce Wnt-2, Wnt-3a, and Wnt-
5a gene expression in prostatic stromal cells. 
To determine the role of paracrine Wnt signaling on the epithelial 
response to androgen ablation, the proliferation of prostatic epithelial cells was 
measured in the presence of conditioned media collected from either 
Tgfbr2floxE2/floxE2 or Tgfbr2fspKO stromal cell cultures. As seen in Figure 14B, 
bicalutamide treatment had little proliferative effect on either stromal cell type 
grown in culture, as measured by 3H-thymidine incorporation assays. As 
anticipated, the Tgfbr2fspKO stromal cells were notably more proliferative than the 
Tgfbr2floxE2/floxE2 stromal cells. Bicalutamide treatment decreased the proliferation 
of the androgen responsive prostate cancer line, LNCaP epithelial cells, as 
expected. Therefore, LNCaP cells were subsequently used as the target epithelia 
to assess proliferative responsiveness to conditioned stromal media treatment 
and androgen ablation. Control green fluorescent protein (GFP)-transduced 
Tgfbr2floxE2/floxE2-conditioned media had lower proliferative response on LNCaP 
cells compared to the enhanced proliferation using the GFP-transduced 
Tgfbr2fspKO-conditioned media (Figure 14C and Figure 15). Wnt expression by the 
stroma was antagonized through adenoviral expression of SFRP-2 to stromal cell 
cultures. The SFRP-2 transduced Tgfbr2fspKO-conditioned media significantly 
decreased proliferation of LNCaP cells, compared to GFP-transduced 
Tgfbr2fspKO-conditioned media. Bicalutamide treatment to the Tgfbr2fspKO stroma 
during generation of conditioned media (Bic on Stro) further decreased LNCaP 
proliferation, demonstrating the paracrine effect of androgen ablation on epithelial  
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Figure 15. Bicalutamide treatment directly to prostatic stromal cells leads 
to a paracrine mediated increase in epithelial proliferation whereas 
bicalutamide treatment to the epithelia directly causes a decrease in 
proliferation. 3H-thymidine incorporation assays were performed on LNCaP 
epithelial cells also treated with or without bicalutamide for five days. Each bar 
represents the average of three or more replicates and error bars indicate 
standard deviation. Asterisks indicate significance compared to the respective 
control. GFP-Tgfbr2floxE2/floxE2 and GFP-Tgfbr2fspKO stromal cells treated with 
bicalutamide generated ‘Bic on Stro’ conditioned media (see figure 14) Figure 
taken from (Placencio, Sharif-Afshar et al. 2008). 
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cells. However, most dramatic was the direct effect of androgen ablation on the 
epithelia with SFRP-2 transduced Tgfbr2fspKO-conditioned stromal media (Bic on 
Epi), which resulted in a 50% decrease in LNCaP proliferation compared to the 
GFP-transduced Tgfbr2fspKO-conditioned stromal media control. This suggested 
that Wnt ligands expressed by both Tgfbr2floxE2/floxE2 and Tgfbr2fspKO stromal cells 
support epithelial survival in response to androgen antagonism. 
Next, the role of TGF- on Wnt expression during androgen ablation in 
mice was determined. Previously, SFRP-2 has been shown to inhibit Wnt-3a, 
and Wnt-5a in vivo (Hou, Tan et al. 2004; Liu, Kirschenbaum et al. 2007). Based 
on SFRP-2 mediated inhibition of prostatic epithelial cell proliferation in vitro, we 
hypothesized that it may restore androgen dependence to the Tgfbr2fspKO 
prostate. The fragile condition of Tgfbr2fspKO mice did not allow expression of 
SFRP-2 in these mice directly. Therefore, we transduced control GFP or SFRP-2 
adenovirus in intact Tgfbr2floxE2/floxE2 and Tgfbr2fspKO prostate lobes and 
subsequently allografted the tissues under the renal capsules of SCID mice in 
tissue rescue experiments. GFP staining confirmed successful transduction of 
the allografted tissues (Figure 16). Three days following allografting the host 
mice were either left intact or castrated for an additional three days. There were 
no observable differences in apoptotic rate resulting from the expression of GFP 
or SFRP-2 on Tgfbr2floxE2/floxE2 and Tgfbr2fspKO rescued prostates in the intact host 
mice, based on TUNEL staining (Figure 17). Following castration of the host 
mice, the Tgfbr2floxE2/floxE2 prostates had the expected elevation of TUNEL 
staining in both GFP and SFRP-2 transduced prostates (Figure 18 A, B). The  
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Figure 16. GFP staining indicates successful adenovirus allograft 
transduction. GFP immunohistochemistry staining is positive in both GFP and 
SFRP2 tissue rescue allografts (see  Figure 18). Figure taken from (Placencio, 
Sharif-Afshar et al. 2008). 
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Figure 17. Inhibition of Wnt signaling does not alter prostate phenotypes of 
intact Tgfbr2floxE2/floxE2 or Tgfbr2fspKO mice. (A) Tgfbr2floxE2/floxE2 or Tgfbr2fspKO 
mature mouse prostates were transduced with GFP or SFRP2 adenovirus and 
allografted in the renal capsules of male SCID mice. Tissues were harvested on 
day six (n=12) and subjected to H&E staining. (B) Tgfbr2floxE2/floxE2 or Tgfbr2fspKO 
mature mouse prostates were transduced with GFP or SFRP2 adenovirus and 
allografted in the renal capsules of male SCID mice. Tissues were harvested on 
day six (n=12) and subjected to TUNEL staining for apoptotic cells (brown). Scale 
bar indicates 25µM. Figure taken from (Placencio, Sharif-Afshar et al. 2008). 
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Figure 18. Inhibition of Wnt signaling restores Tgfbr2fspKO prostate 
responsiveness to androgen ablation. (A) Tgfbr2floxE2/floxE2 or Tgfbr2fspKO 
mature mouse prostates were transduced with GFP adenovirus and allografted in 
the renal capsules of male SCID mice. Host mice were castrated for three days. 
Tissues were harvested on day six (n=12) and subjected to H&E staining (upper 
panels) as well as TUNEL staining (lower panels) for apoptotic cells (brown). (B) 
Tgfbr2floxE2/floxE2 or Tgfbr2fspKO mature mouse prostates were transduced with 
SFRP-2 adenovirus and allografted in the renal capsules of male SCID mice. 
Host mice were castrated for three days. Tissues were harvested on day six 
(n=12) and subjected to H&E staining (upper panels) as well as TUNEL staining 
(lower panels) for apoptotic cells (brown). Percent positive epithelial TUNEL 
positive staining was not statistically different between GFP-Tgfbr2floxE2/floxE2 and 
SFRP-2-Tgfbr2floxE2/floxE2 allografts (P value = 0.2819). Percent positive epithelial 
TUNEL positive staining in SFRP-2- Tgfbr2fspKO allografts was statistically greater 
than GFP-Tgfbr2fspKO allografts (P value = 0.0373). (C) Tissue recombinations of 
12T7f LADY epithelial organoids and Tgfbr2fspKO prostatic stromal cells were 
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allografted in SCID mice for six weeks. The host mice were given GFP 
adenovirus throughout the grafting period. Host mice were castrated seven days 
prior to harvesting the prostatic grafts. Tissue recombinants were harvested at 
week six (n=4) and subjected to H&E staining (upper panel) as well as TUNEL 
staining (lower panel) for apoptotic cells (brown). (D) Tissue recombinations of 
12T7f LADY epithelial organoids and Tgfbr2fspKO prostatic stromal cells were 
allografted in SCID mice for six weeks. The host mice were given SFRP-2 
adenovirus throughout the grafting period. Host mice were castrated seven days 
prior to harvesting the prostatic grafts. Tissue recombinants were harvested at 
week six (n=4) and subjected to H&E staining (upper panel) as well as TUNEL 
staining (lower panel) for apoptotic cells (brown). Percent positive epithelial 
TUNEL positive staining in tissue recombinations of 12T7f LADY epithelial 
organoids and SFRP-2-Tgfbr2fspKO allografts was statistically greater than those 
in tissue recombinations of 12T7f LADY epithelial organoids and GFP-Tgfbr2fspKO 
allografts (P value = 0.0472). Scale bar indicates 25 µm. Figure taken from 
(Placencio, Sharif-Afshar et al. 2008). 
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expression of GFP with Tgfbr2fspKO prostates recapitulated the original 
observation of refractivity to androgen ablation. TUNEL-positive epithelia in GFP-
Tgfbr2floxE2/floxE2 prostates, three days following castration, were significantly 
elevated compared to GFP-Tgfbr2fspKO prostates. Note, in comparison, the 
expression of SFRP-2 resulted in a three-fold increase in the apoptosis of 
Tgfbr2fspKO prostates following castration similar to Tgfbr2floxE2/floxE2 prostates. The 
restoration of prostate regression in SFRP-2-Tgfbr2fspKO prostates following 
castration indicated cooperation among the TGF-, Wnt, and androgen signaling 
pathways.  
 
Stromal TGF- signaling allows prostatic ductal regression after androgen 
ablation in prostate cancer 
Next, the role of stromal TGF- signaling in a prostate cancer model 
system was examined. Our objective was to determine if the paracrine instruction 
from the stroma to the epithelia observed in the development of androgen 
refractory PIN lesions continued to have an androgen refractory influence in the 
progression from PIN to adenocarcinoma. This was achieved by allografting 
tissue recombinants consisting of Tgfbr2floxE2/floxE2 or Tgfbr2fspKO stromal cells with 
prostate epithelial organoids from a prostate cancer mouse model expressing the 
SV40 Large T Antigen in the epithelia, 12T7f LADY (Kasper, Sheppard et al. 
1998 ). Host male SCID mice were treated weekly with either SFRP-2 or GFP 
control adenovirus. Five weeks following allografting, half of the host mice were 
castrated. All grafts were analyzed six weeks following grafting. The GFP-  
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Figure 19. Inhibition of Wnt signaling in Tgfbr2floxE2/floxE2- and Tgfbr2fspKO-
stroma allografts with LADY Tag organoids. (A) Tissue recombinations of 
12T7f LADY epithelial organoids and Tgfbr2floxE2/floxE2 or Tgfbr2fspKO prostatic 
stromal cells were allografted in SCID mice for six weeks. The host mice were 
given GFP adenovirus or SFRP2 throughout the grafting period. Tissue 
recombinants were harvested at week six (n=4) and subjected to H&E staining 
(upper panels) as well as TUNEL staining (lower panels) for apoptotic cells 
(brown). (B) Tissue recombinations of 12T7f LADY epithelial organoids and 
Tgfbr2fspKO prostatic stromal cells were allografted in SCID mice for six weeks. 
The host mice were given GFP or SFRP2 adenovirus throughout the grafting 
period. Tissue recombinants were harvested at week six (n=4) and subjected to 
H&Estaining (upper panels) as well as TUNEL staining (lower panels) for 
appropriate cells (brown). Figure taken from (Placencio, Sharif-Afshar et al. 
2008). 
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Figure 20. SV40 positive epithelia within tissue recombination allografts. 
SV40 T antigen staining localizes LADY epithelia within the tissue recombination 
allografts using Tgfbr2floxE2/floxE2 or Tgfbr2fspKO prostatic stromal cells. Shown are 
representative prostate glands from GFP or SFRP2-Tgfbr2floxE2/floxE2 allografts.  
Tgfbr2fspKO allografts had similar epithelial staining (data not shown). Figure taken 
from (Placencio, Sharif-Afshar et al. 2008). 
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Tgfbr2floxE2/floxE2 stroma grafts (with LADY organoids) formed prostatic ductal 
structures with minimal hyperplasia (Figure 19A, 19B, and 20). Following 
castration, the GFP- Tgfbr2floxE2/floxE2 stroma-associated grafts had elevated 
TUNEL-positive apoptotic epithelia. In contrast, GFP-Tgfbr2fspKO stroma-
associated grafts developed adenocarcinoma (Figure 18C, upper panel). The 
GFP-Tgfbr2fspKO stroma-associated grafts had low levels of apoptosis (Figure 
18C, lower panel). SFRP-2-Tgfbr2floxE2/floxE2 and GFP-Tgfbr2floxE2/floxE2 stroma-
associated grafts were similar in regard to apoptotic response to androgen 
ablation. Notably, the SFRP-2-Tgfbr2fspKO stroma-associated grafts had elevated 
levels of TUNEL-positive epithelia following castration, typical of normal prostate 
regression (Figure 18D lower panel). We also found that the SFRP-2-Tgfbr2fspKO 
stroma-associated grafts appeared more differentiated than analogous GFP-
Tgfbr2fspKO stroma-associated grafts. Thus, stromal androgen and TGF- 
signaling cooperates with epithelial Wnt signaling to regulate responsiveness to 
androgen ablation in benign, pre-neoplastic, and adenocarcinoma of the 
prostate. These results are summarized (Figure 21). 
 
Discussion 
 
Stromal responsiveness to TGF- allows androgen sensitivity in the 
prostate epithelia through paracrine Wnt signaling. The direct role of TGF- 
signaling on the prostate epithelia following castration was minimal based on 
histologic and apoptotic differences between the Tgfbr2NKX3.1KO and  
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Figure 21. Summary diagram depicting that the loss of stromal TGF- 
signaling influences the development of CRPC.  A representative prostate 
gland is depicted. The epithelia (blue rounded rectangles) comprise the prostate 
ducts, which are surrounded by the stroma (pink half moons). The diagram 
depicts that the loss of the TGF- type II receptor in the stroma leads to 
production of Wnt ligands (pink arrow). Through paracrine signaling, these Wnts 
in the stroma signal to the epithelia (pink to blue gradient arrow) resulting in 
castrate resistance. Inhibition of these Wnts with SFRP2 restored the castrate 
responsiveness of the epithelia. Summarized from (Placencio, Sharif-Afshar et al. 
2008). 
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Tgfbr2floxE2/floxE2 prostates. It is possible that compensatory signaling by Activin 
and its cognate receptors may provide Smad protein activity similar to TGF-. 
However, the conditional knockout of the TGF- type II receptor in fibroblasts, in 
the Tgfbr2fspKO mice and tissue recombinants, indicated the importance of TGF- 
responsiveness in the stromal compartment following castration. Further crossing 
of the Tgfbr2fspKO mice to the TOPGal reporter gene mouse model demonstrated 
the regulatory role of stromal TGF- signaling on Wnt signaling in epithelial cells 
refractory to androgen ablation. The Tgfbr2fspKO stromal cells themselves 
acquired a more proliferative phenotype, presumably due to the loss of the 
growth inhibitory TGF- signaling, and promoted nearby epithelia to increase 
their rate of proliferation and overcome hormonal dependence. The mechanisms 
behind the observed phenomena highlight a stromal derived paracrine Wnt 
signaling axis that is triggered upon androgen ablation. The stark proximal ductal 
localization of canonical Wnt signaling activity in control prostates following 
castration indicated duplicity of responses to androgen ablation, one of survival 
and another for cell death. Thus, the data indicate that the role for TGF-
signaling following androgen ablation is to suppress Wnt signals in much of the 
distal prostate to enable regression.  
The stem cell niche is regulated by TGF- and Wnt signaling. Prostate 
regression-regeneration cycles surpassing 30 cycles in a single mouse suggest 
the presence of prostate epithelial stem cells (Isaacs 1987). Prostate stem cells 
are not well defined, but studies have focused on identifying their location within 
the basal cells in the proximal ducts (De Marzo, Nelson et al. 1998; Zhou, 
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Flesken-Nikitin et al. 2007). Our studies also indirectly suggest the presence of a 
prostate stem cell niche in the proximal ductal epithelia (Figure 12). The lack of 
-gal staining in Tgfbr2floxE2/floxE2 prostates compared to widespread expression in 
Tgfbr2fspKO/TOPGal prostates indicates that stromal TGF- signaling regulates 
the spatial localization of canonical Wnt signaling. Of greater significance in 
relation to the stem cell niche is revealed after castration. Three days following 
castration Tgfbr2floxE2/floxE2/TOPGal prostates exhibit transient -gal expression in 
the proximal ductal epithelia compared to widespread expression in 
Tgfbr2fspKO/TOPGal prostates. Based on known information, these studies reveal 
the cooperation of TGF-, androgen, and Wnt signaling in regulating the prostate 
stem cell niche. Characteristics to suggest that the proximal epithelial ducts 
contain a stem cell population include having a high in vitro proliferative potential, 
are slow cycling, and can reconstitute highly branched glandular ductal structures 
in collagen (Reya, Morrison et al. 2001; Tsujimura, Koikawa et al. 2002). Using 
NRP-152 rat epithelial cells in tissue recombination studies, both basal and 
luminal epithelial cells were shown to be derived from a common progenitor 
(Hayward, Haughney et al. 1999). These studies suggested it was due to cells 
within the basal population that were capable of differentiating into both cell 
types. The proximal ducts are known to be surrounded by a thick layer of smooth 
muscle cells rich in TGF- (Nemeth, Sensibar et al. 1997). This TGF- gradient 
is thought to help maintain the stem cell niche by inhibiting proliferation. 
Furthermore, expression of a dominant negative Tgfbr2 in the prostate caused 
increased proliferation of the proximal ductal epithelia (Kundu, Kim et al. 
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2000).The protective effects within the stem cell niche by TGF- was shown in a 
castration study. TGF- receptor levels transiently increased following castration, 
with a peak at four days and diminished by 14 days (Kyprianou and Isaacs 
1988). Prostate regression is greatest between three to seven days following 
castration and lessens by 14 days and thereafter. However, even after full 
regression at two months the prostate does not ever diminish completely, but 
remains as a small bud of proximal ductal epithelia thought to encompass the 
stem cells. This suggests that TGF- was essential to maintain the stem cell 
niche with an increased need during regression. A gene profiling study revealed 
TGF- signaling in maintaining stem cells with mouse embryonic and adult 
prostates (Blum, Gupta et al. 2009). In addition, embryonic stem cells relied on 
canonical Wnt signaling associated with proliferation and self-renewal, whereas 
adult stem cells used the non-canonical Wnt/Ca+ signaling pathway to maintain 
quiescence. Another study suggested that Wnt signaling regulates self-renewal 
of prostate cancer cells with stem cell characteristics independent of androgen 
receptor activity (Bisson and Prowse 2009). In particular, Wnt-3a increased self-
renewal and prostasphere size in LNCaP and C4-2B cells. These studies in 
combination with our Tgfbr2floxE2/floxE2/TOPGal and Tgfbr2floxE2/floxE2/TOPGal 
studies indicate TGF- as a master regulator in inhibiting widespread canonical 
Wnt signaling under normal conditions. Following androgen ablation, TGF- 
transiently increases, triggering a transient increase in canonical Wnt signaling 
within the proximal ducts to maintain the stem cell niche during regression. This 
76 
emphasizes the potential for Wnt inhibitors to treat CRPC in combination with 
currently used androgen ablation regimens. 
Previous studies have shown that Wnt genes or proteins in the Wnt 
signaling pathway are up-regulated or mutated in castrate resistant prostate 
cancers (Terry, Yang et al. 2006; Verras and Sun 2006). Castration provided a 
transient elevation of canonical Wnt signaling in Tgfbr2floxE2/floxE2 prostates (Figure 
12). In parallel, Tgfbr2floxE2/floxE2 prostatic stromal cells transiently express specific 
Wnt genes in response to an androgen antagonist, bicalutamide (Figure 14). In 
contrast, Tgfbr2fspKO stromal cells had elevated basal expression of Wnt-2, Wnt-
3a, and Wnt-5a. Recently, preosteoblasts were reported to induce Wnt signaling 
as a result of androgen stimulation, and through paracrine signaling the 
preosteoblasts subsequently increased the proliferation of prostate cancer cells 
in a coculture system in vitro (Kim, Zelner et al. 1996). As preosteoblasts and 
prostatic stromal cells are both of mesenchymal origin, together with the results 
presented, this suggests a directional regulation of paracrine Wnt signaling by 
androgens. LNCaP cells, used in our co-culture studies, are derived from a 
human prostate cancer lymph node metastatic lesion that lack a functional TGF- 
type II receptor and have a functional, yet mutant, androgen receptor (Yardy and 
Brewster 2005). The LNCaP cells, analogous to the Tgfbr2NKX3.1KO prostates, 
enabled us to show that androgen responsiveness mediated by the stroma is not 
dependent on epithelial TGF- signaling. This supports earlier developmental 
studies in the prostate. The prostate stroma, but not the epithelia was shown to 
dictate androgen response in the prostate (Cunha and Chung 1981). 
77 
Antagonizing Wnt signaling in the absence of androgen ablation in 
Tgfbr2floxE2/floxE2 and Tgfbr2fspKO prostates did not induce apoptosis (Figure 18). 
Thus, although TGF- and androgen signaling converge in the stroma to affect 
canonical Wnt signaling they act through distinct pathways.  
 
We demonstrated that activated canonical Wnt signaling helps to limit 
prostatic regression. It is known that Wnt ligands bind Frizzled receptors on the 
epithelial surface and transmit signals through the canonical pathway that 
activates -catenin/TCF in the nucleus (Sugimura, Cunha et al. 1986). Activating 
mutations in -catenin have been identified to affect androgen receptor 
transcriptional activity and ligand specificity (Truica, Byers et al. 2000; Chen, 
Shukeir et al. 2004). Based on the specific TCF/-catenin activity in the proximal 
prostatic ducts of the castrated Tgfbr2floxE2/floxE2/TOPGal mice, the mechanism for 
the survival of the proximal ducts may be through an initial activation of epithelial 
canonical Wnt signaling. Comparing the Tgfbr2floxE2/floxE2/TOPGal and 
Tgfbr2fspKO/TOPGal mice it was evident that TGF- signaling is important to 
regulate the spatial localization of Wnt signaling to enable regression of the distal 
ducts in a temporal coordination with androgen signaling. TGF- is distributed in 
a gradient throughout the prostate stroma, with the highest concentration residing 
at the proximal ducts (Nemeth, Sensibar et al. 1997). This is consistent with 
studies showing androgen-induced regeneration occurring at the distal tips of the 
prostate (Polakis 2000). One mechanism by which the localization of Wnt 
signaling is limited could be due to secreted Wnt inhibitors (e.g. SFRP-2, DKK-1) 
in the distal glands. Long term androgen ablation responses were not studied, as 
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the focus of the study was to determine the role of the immediate upregulation of 
TGF- following androgen ablation. However, as the prostate continues to 
regress after day seven, Wnt signaling apparently is replaced by another 
mechanism to prevent continued regression of the proximal ducts. The latter 
events and maintenance of the regressed prostate is through a separate 
mechanism that is more dependent on the availability of androgens since some 
prostate regression was observed in Tgfbr2fspKO mice 14 days following 
castration (Figure 10).  
Together, the upregulation of TGF- expression in the prostate, coincident 
with androgen ablation, would support the regression of the prostate by 
antagonizing stromal Wnt expression brought on from an androgen regulated 
mechanism. In normal proximal prostatic tissue the epithelial Frizzled receptor is 
activated resulting in canonical, and possibly non-canonical, Wnt signaling which 
may contribute to the phenotypes seen in our mouse models. However, based on 
previous reports that canonical Wnt signaling supports survival and proliferation 
(Wright, Douglas et al. 1999; Widelitz 2005), this is the most likely mechanism 
that maintains the viability of proximal prostate tissues in the context of androgen 
ablation. The entire prostate does not involute in the absence of androgens, 
since subsequent replacement of testosterone results in the regeneration of 
prostatic tissue (Knudson, Hethcote et al. 1975). Intriguingly, in other mammals 
such as deer, antler regeneration is reported to demonstrate a site-specific Wnt 
signaling activation during regeneration (Mount, Muzylak et al. 2006). The fact 
that activating mutations of -catenin are found in castrate resistant prostate 
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cancers (Voeller, Truica et al. 1998; Truica, Byers et al. 2000 ) suggests that 
cancer cells can hijack the same Wnt signaling pathways used to support 
proximal prostate survival to aid in tumor survival. Understanding paracrine 
interactions of TGF-, androgen, and Wnt signaling in regulating prostate 
regression may be linked to its regeneration following androgen supplementation.  
Stromal-epithelial interactions have proven to be important in embryonic 
development and tumorigenesis. Based on the Knudson multi-hit hypothesis of 
tumor development we attempted to further the progression of the PIN lesions 
associated with LADY 12T7f epithelia, expressing the large T antigen, by 
recombining them with Tgfbr2fspKO prostatic stromal cells, as the second 
mutagenic hit (Knudson, Hethcote et al. 1975). Figure 6 illustrated that the Wnt 
signaling associated with the Tgfbr2fspKO cells not only enabled the PIN lesions to 
progress to adenocarcinoma, but also enabled the epithelia to become resistant 
to androgen ablation. Inhibition of Wnt signaling with SFRP-2 appeared to restore 
the androgen sensitivity and decrease the tumorigenicity of the resulting tumors. 
Future prostate cancer therapies would most likely benefit by not only 
antagonizing the traditional androgen signaling pathway, but also inhibiting Wnt 
signaling. This would allow therapies to target both the epithelial and stromal 
compartments as well as androgen dependent and independent tumor cells. 
Our studies concentrated on canonical stromal TGF- signaling. We 
showed that the loss of stromal TRII led to transformation of the epithelia as 
well as castrate resistance. Studies have shown that the downstream Smad 
proteins can activate different pathways depending on the transcriptional 
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complexes they form with binding DNA and activating target genes. It would be 
interesting to determine if Smad2, Smad3, or Smad4 played similar or different 
roles with respect to pathways influencing transformation or castrate resistance. 
It has been shown that AR can bind Smad3 directly, but not Smad2 (Chipuk, 
Cornelius et al. 2002). In addition, Smad4 controls the ability of Smad3 to inhibit 
AR-mediated gene transcription (Nishi, Oya et al. 1996). This suggests that 
Smad3 and Smad4 would have a greater role in androgen regulated events 
including castrate resistance compared to Smad2.  In a breast cancer model 
using the MMTV-Neu mouse, activated Smad2 correlated with loss of the TRII 
receptor (Landis, Seachrist et al. 2005). In prostate cancer, the loss of TRII is 
found in the majority of patient samples suggesting that Smad2 may play a 
greater role in prostate transformation. In our Tgfbr2fspKO mouse model it is not 
possible to delineate the contribution of individual Smad proteins to 
transformation or castrate resistance. Further understanding would make 
targeting castrate resistance in late stage prostate cancer versus transformation 
as a preventative or early stage treatment possible. 
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CHAPTER III 
 
BONE MARROW DERIVED MESENCHYMAL STEM CELLS INCORPORATE  
INTO THE PROSTATE DURING REGROWTH 
 
Introduction 
 Prostate cancer mortality continues to rise as the aging population 
expands. After surgical intervention, radiation, and androgen ablation therapy, 
recurrence is androgen-independent and is termed castrate resistant prostate 
cancer (CRPC). Patients with CRPC are primarily given palliative care since 
conventional chemotherapeutics do little to delay mortality from the disease. 
Prostate growth and regrowth has been the subject of stem cell studies, but not 
with respect to recruited cell types (Tsujimura, Koikawa et al. 2002; Wang, 
Kruithof-de Julio et al. 2009). We used transgenic mouse models to help 
understand the involvement of recruited cells in prostate regrowth. 
Prostatic epithelial Wnt signaling was identified in transgenic mouse 
models of CRPC. One such model we developed had a conditional stromal 
knockout of the TGF- type II receptor, termed Tgfbr2fspKO, (Bhowmick, Chytil et 
al. 2004). FSP1-Cre enabled targeted recombination in mesenchymal-derived 
cells, including fibroblasts (Iwano, Plieth et al. 2002; Bhowmick, Chytil et al. 
2004). The prostatic stroma of Tgfbr2fspKO mice independently contributed to 
transformation of the adjacent epithelia as well as castrate resistance. The 
mechanism for the castrate resistant phenotype was associated with stromal 
fibroblastic expression of Wnt ligands, that in turn activated canonical Wnt 
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signaling in the epithelia (Li, Placencio et al. 2008; Placencio, Sharif-Afshar et al. 
2008). Adenoviral transduction of the Wnt signaling antagonist, secreted frizzled 
related protein-2 (SFRP2) restored castrate responsiveness in the Tgfbr2fspKO 
mice (Placencio, Sharif-Afshar et al. 2008). However, systemic SFRP2-
adenovirus treatment in Tgfbr2fspKO mice was associated with morbidity. Another 
model with prostatic epithelial expression of constitutively activated -catenin 
developed HGPIN and sustained growth following castration (Yu, Wang et al. 
2009). Additionally, human CRPC C4-2B cells reportedly have elevated autocrine 
Wnt signaling compared to their androgen dependent parent cell line, LNCaP 
(Bisson and Prowse 2009).  
CRPC, tissue remodeling, and cancer progression are generally 
associated with the recruitment of bone marrow derived cells (Liu, Chen et al. 
2006; Houghton, Morozov et al. 2007; Ammirante, Luo et al. 2010). In a mouse 
model of damaged liver, during regeneration the recruited BMDCs contributed to 
the new liver epithelia (Vassilopoulos, Wang et al. 2003). Similar BMDC 
incorporation occurs in gastrointestinal epithelia associated with elevated 
proliferation and inflammation (Houghton, Stoicov et al. 2004; Davies, Powell et 
al. 2009). A specialized type of BMDCs, mesenchymal stem cells (MSCs), are 
recruited to sites of inflammation and proliferation including wound healing and 
cancer (Ichim, Alexandrescu et al. 2010). Multipotent MSCs can differentiate into 
multiple cell types including osteoblasts, chondrocytes, adipocytes, and 
fibroblasts (Bianco, Robey et al. 2008). In various models of cancer, MSCs 
potentiate disease progression. In a model of breast cancer, MSCs promoted 
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metastasis (Karnoub, Dash et al. 2007). In a model of prostate cancer 
metastasis, manipulating MSCs to deliver the urokinase-type plasminogen 
antagonist amino-terminal fragment by co-injection with PC3 cells in the bone 
decreased tumor angiogenesis and osteolytic activity (Fritz, Noel et al. 2008). 
MSCs home to tumors as a result of cytokine and chemokine expression in the 
tumor microenvironment. The efficacy of MSCs as a therapeutic tool has been 
tested through the targeted delivery of exogenously expressed soluble factors 
(Fritz and Jorgensen 2008; Reinders, Fibbe et al. 2010). For example, patients 
with heart damage have received MSCs that home to damaged and necrotic 
tissue for wound repair (Song, Song et al. 2010). We rationalized that MSC 
therapy may benefit patients with CRPC in a similar manner. 
We examined BMDC recruitment to the prostate during regrowth. Co-
expression of prostate markers with BMDCs suggested that these recruited cells 
were also incorporated into the prostate epithelia. We further identified MSCs 
fusing with prostatic epithelia. Using an orthotopic C4-2B xenograft model 
system, we found that recruited MSCs could further contribute to tumor 
progression by enhanced Wnt signaling. The overexpression of SFRP2 by MSCs 
homed to the tumors and restored tumor responsiveness to castration. 
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Materials and Methods 
 
Ethics Statement 
 
The Vanderbilt Institutional Animal Care and Use Committee approved all animal 
procedures (M/06/236). 
 
Mice and Fetal Liver Transplants 
 
Harlan C57BL/6 wild type mice were purchased (Harlan, Indianapolis, IN). 
Chicken beta actin-GFP mice were purchased from Jackson Laboratories and 
GFP expression was confirmed by visualization with UV light. Tgfbr2floxE2/floxE2 
(Chytil, Magnuson et al. 2002) and Tgfbr2fspKO (Bhowmick, Chytil et al. 2004) 
mice with C57BL/6 background were generated as previously described. Fsp-
Cre+/Rosa26 mice enabled -gal visualization of cells after Cre-mediated 
recombination. All mice were genotyped from ear punch biopsies as previously 
reported (Kasper, Sheppard et al. 1998; DasGupta and Fuchs 1999; Chytil, 
Magnuson et al. 2002). Fetal liver transplants (FLTs) were performed as 
previously described (Everhart, Han et al. 2005). Briefly, E14 embryonic livers 
from GFP+ mice were made into single cell suspensions for tail vein injections 
(2x106 cells per mouse) into lethally irradiated recipient male mice using a [137Cs] 
gamma source by giving a split dose of 1200 rads. The host mice were either 
intact or castrated four weeks prior to the FLT procedure. To minimize infection 
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from a diminished immune system, mice were kept on acidified antibiotic water 
for two weeks before and four weeks after FLT. Four weeks after FLT, prostate 
regrowth was monitored following subcutaneous implantations of testosterone 
pellets.   
 
Laser Capture Microdissection and RNA Isolation for Microarray 
 
Tgfbr2floxE2/floxE2 and Tgfbr2fspKO mouse prostates were dissected and frozen in 
liquid nitrogen. Cryosections of the prostates were used for laser capture 
microdissection of the stroma. RNA was isolated using a µMACS mRNA isolation 
kit following the manufacturer‟s protocol (Miltenyi Biotec, Auburn, CA). Samples 
were lysed in SuperAmp Lysis Buffer and sent for processing and microarray 
analysis. Miltenyi Biotec amplified the RNA, produced cDNA, and hybridized to 
Agilent whole genome oligo microarrays. Fluorescent signals were detected and 
Agilent Feature Extraction Software was used to read and process the 
microarray image files. Gene lists were given as normalized Cy5/Cy3-fold 
changes. The microarray data sets were submitted to the NCBI GEO database 
accession number GSE22130. The selected table included fold change values 
averaged from three data sets per genotype, each having a fold change >2 and 
p-value <0.01. 
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MSC generation and verification 
 
Bone marrow derived mesenchymal stem cells were derived as previously 
described (Phinney, Kopen et al. 1999; Spagnoli, Longobardi et al. 2005; 
Anumanthan, Makari et al. 2008). Bone marrow was flushed from mice femurs 
and tibias aged eight to twelve weeks. Red blood cells were lysed and the 
remaining bone marrow cells plated in MSC expansion media (Phinney, Kopen et 
al. 1999; Spagnoli, Longobardi et al. 2005). Adherent MSCs were selected and 
expanded for ten days. Cells were then trypsinized and plated for differentiation 
assays or used for tail vein injections into host mice (106 cells injected per 
mouse). 
 Osteogenic differentiation of MSCs was performed as previously 
described (Phinney, Kopen et al. 1999; Alfaro, Pagni et al. 2008). MSCs were 
switched to osteogenic inducing media for three weeks, consisting of high 
glucose DMEM supplemented with 10% fetal bovine serum, 100 µM 
dexamethasone, 0.1 mM ascorbic acid, and 10nM -glycerophosphate. 
Osteogenic differentiation was confirmed by alkaline phosphatase staining 
according to the manufacturer‟s directions (Sigma-Aldrich, St. Louis, MO)  
 Chondrogenic differentiation of MSCs was performed as previously 
described (Phinney, Kopen et al. 1999; Alfaro, Pagni et al. 2008). MSCs were 
switched to chondrogenic inducing media for three weeks, consisting of high 
glucose DMEM supplemented with 10% fetal bovine serum, 100µM 
dexamethasone, and 0.1 µg/mL TGF-. Chondrogenic differentiation was 
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confirmed by alcian blue (pH 1.0) staining. Cells were fixed for 20 min at RT in 
10% formalin, washed with PBS, stained with alcian blue for 20 min and washed 
with PBS. 
 Adipogenic differentiation of MSCs was performed as previously described 
(Phinney, Kopen et al. 1999; Alfaro, Pagni et al. 2008). MSCs were switched to 
adipogenic inducing media for three weeks, consisting of high glucose DMEM 
supplemented with 10% fetal bovine serum, 10µM dexamethasone, 10µg/ mL 
insulin, and 100µg/mL IBMX. Adipogenic differentiation was confirmed by Oil 
Red-O staining.  
  
 
Immunohistochemistry and Immunofluorescence 
 
Tissues were fixed with 4% paraformaldehyde or 10% formalin, embedded in 
paraffin, and sectioned for histological analysis. GFP (1:1000, Santa Cruz, CA) 
and phosphorylated-histone H3 (1:500, Upstate, Temecula, CA) 
immunohistochemistry was performed using antigen retrieval with antigen 
unmasking solution (Vector Laboratories, Burlngame, CA) diluted 1:100. 
Following primary antibody incubation overnight, Dako Cytomation Universal or 
Rabbit kits were used for the secondary antibody and development with DAB. 
TUNEL staining was performed using the ApopTag Peroxidase In Situ Apoptosis 
Detection Kit (Millipore, Temecula, CA) as directed. Immunohistochemical 
staining was quantitated by taking a ratio of positively stained cells per field 
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(400x) MetaMorph 7.6 software was used to help quantitate the 
immunohistochemical staining. Statistical significance was determined by two 
tailed Student‟s t test.  
 Tissues were fixed with 4% paraformaldehyde or 10% formalin, embedded 
in paraffin, and sectioned for histological analysis. Antigen retrieval with antigen 
unmasking solution (Vector Laboratories, Burlngame, CA) diluted 1:100 was 
performed. Staining was performed for GFP (1:100, Santa Cruz, CA), -
galactosidase (1:750, Abcam, Cambridge MA), Cytokeratin 8 (1:100, University 
of Iowa Hybridoma Bank, Iowa City, IA), p63 (1:50, Calbiochem, Gibbstown, NJ), 
androgen receptor (1:50, Santa Cruz, CA), and CD45 (1:50, BD Biosciences, 
San Jos, CA). Secondary anti-mouse or anti-rabbit Alexa Fluor 594 (red), Alexa 
Fluor 546 (orange-red) or Alexa Fluor 488 (green) were used as indicated (1:500, 
Invitrogen, Carlsbad, CA). TO-PRO-3 iodide was used for confocal nuclear 
counterstaining (Invitrogen, Eugene, OR). DAPI mounting media was used for 
widefield immunofluorescence staining (Vector Laboratories, Burlngame, CA). 
Widefield images were taken on a Nikon epifluorescence microscope and a Leica 
DM IRB inverted microscope. Z-series slices were taken on a Zeiss LSM510 
META inverted confocal microscope. 
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Statistical Analysis 
 
Oneway ANOVA was performed to test differences between the experimental 
and control groups, followed by Dunnett‟s post-hoc tests when the variances 
were equal. When variances were unequal, oneway Welch ANOVA allowing for 
unequal variances was used to test differences between the experimental groups 
and the intact group, followed by a two-sample t tests with unequal variances. 
 
 
Results 
 
Castrate resistance mediated by the stroma and prostate regrowth  
recruit BMDCs 
 Previous studies with the Tgfbr2fspKO mouse model showed that the 
conditional stromal knockout of TGF- signaling led to CRPC (Placencio, Sharif-
Afshar et al. 2008). To fully understand the stromal changes that led to the 
development of CRPC, we isolated prostate stroma RNA through laser capture 
microdissection for microarray analysis and compared Tgfbr2fspKO to control 
Tgfbr2FloxE2/FloxE2 mouse stroma. The microarray data has been deposited in the 
NCBI Gene Expression Omnibus (GEO, GSE22130). This revealed the 
differential regulation of numerous cytokines and chemokines in Tgfbr2fspKO 
compared to control Tgfbr2FloxE2/FloxE2 mouse stroma (Table 2). 
Microenvironments rich in chemokine and cytokine signaling recruit many cell 
types, including BMDCs (Alison, Lim et al. 2009).  
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Table 2. Selected chemokines altered in Tgfbr2fspKO mouse stroma 
compared to Tgfbr2FloxE2/FloxE2 mouse stroma. Negative values indicate the 
chemokine was downregulated in the Tgfbr2FloxE2/FloxE2 stroma and upregulated in 
the Tgfbr2fspKO stroma. Positive values indicated the chemokine was upregulated 
in the Tgfbr2FloxE2/FloxE2 stroma and downregulated in the Tgfbr2fspKO stroma. 
Values are averaged from three independent data sets. Each value had > 2-fold 
difference and a P-value < 0.01. 
 
Selected List of Chemokines 
Primary Sequence Name Average Fold Change 
Ccl12 -3.5079 
Ccl19 2.9717 
Ccl5 -70.1794 
Ccl6 -26.8950 
Ccl8 -39.9607 
Ccl9 -11.6369 
Csf1r -9.6176 
Csf2 162.4770 
Cx3cl1 -25.0406 
Cxcl10 -25.4580 
Cxcl12 77.3219 
Cxcl13 -47.1429 
Cxcl16 -20.5419 
Cxcl9 -49.5591 
Epo 40.0280 
Ifna12 38.8468 
Ifnz 159.8488 
Il18 -2.1320 
Il18bp -13.0765 
Il1f8 3.3513 
Il28 10.2366 
Il4 -3.7385 
Il6st -31.2994 
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BMDCs are recruited to the prostate during cancer development. Since 
BMDCs are also recruited during tissue remodeling, we wanted to identify their 
role in prostate regrowth following castration. Previous studies have described 
the histologic identification of macrophage and monocytes recruited in prostate 
cancer (Luo, Tan et al. 2007; Ammirante, Luo et al. 2010). To better localize 
BMDCs during prostate regrowth we generated GFP-bone marrow chimeric wild 
type mice, which were either intact or castrated. Prostate regrowth was 
monitored at day zero, three, seven, and 28 days following implantation of 
exogenous testosterone. Immunohistochemical GFP localization identified 
BMDCs recruited to the prostate during regrowth in response to castration 
(Figure 22). Intact prostates had low basal BMDC recruitment (Figure 22A). 
Castration induced a slight, but statistically significant increase in recruitment 
(Figure 22B). Three and seven days following testosterone supplementation, 
prostates reached the highest levels of recruitment (Figure 22C, D). At 28 days 
following testosterone supplementation, when the prostate was fully regrown, the 
level of detectible BMDCs had fallen, comparable to basal levels (Figure 22E-F). 
Of particular interest was the appearance of BMDCs residing within the epithelial 
compartment (Figure 22F). BMDC recruitment during active prostate remodeling 
is quantitated in Figure 22G. BMDC incorporation in the epithelial compartment 
was observed throughout the duration of recruitment from castration to full 
regrowth. However, the presence of BMDCs at four weeks when the prostates 
had resumed normal homeostasis suggested that BMDCs directly contributed to 
the regenerated prostate tissue. 
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Figure 22. BMDCs were recruited to the prostate during regrowth. Prostates 
from GFP chimeric mice were stained using GFP immunohistochemistry to show 
GFP-BMDC (brown) recruitment to the prostate. A) Intact prostates had low 
basal levels of BMDC recruitment. B) Two months post-castration, prostates 
show a slight but significant increase in BMDCs (p value = 0.0254). C) Castrated 
prostates supplemented with exogenous testosterone for three days show the 
highest levels of BMDC recruitment (p value = 0.0064). D) Castrated prostates 
supplemented with exogenous testosterone for seven days show high levels of 
BMDC recruitment (p value = 0.0084). E) Castrated prostates supplemented with 
exogenous testosterone for 28 days show low levels of BMDC recruitment 
comparable to basal levels (p value = 0.162). F) Higher magnification of 
castrated prostates supplemented with exogenous testosterone for 28 days 
shows BMDC recruitment to epithelial duct cells. Scale bar indicates 50 µm for 
panels A-E and 25 µm for panel F. G) Bar graph quantifies the percentage of 
GFP-positive BMDCs recruited to the prostate at various time points during 
regrowth. 
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We characterized the BMDCs that appeared to incorporate into the 
prostate epithelia. GFP expression was immunolocalized with prostate tissue 
markers (Figure 23). We found that co-expression of GFP with androgen 
receptor indicated the prostate cell lineage of stromal or epithelial cells (Figure 
23A). Furthermore, basal and prostate luminal epithelial cells identified by p63 
and cytokeratin 8, respectively, also co-expressed GFP (Figure 23B, C). We also 
noted limited co-expression of GFP with CD45, indicating hematopoietic lineage 
cells (Figure 23D). These results indicated that although a large population of 
BMDCs is recruited to the prostate, comparatively smaller populations of the total 
BMDC population seem to incorporate into the tissue long term. 
 
MSCs incorporate into the prostate epithelia through fusion 
We hypothesized that at least a subset of the incorporated BMDCs were 
mesenchymal stem cells (MSCs) based on evidence that 1) MSCs are less than 
one percent of the total bone marrow population of cells, 2) MSCs are reported to 
home to sites of active tissue remodeling, and 3) MSCs are known to incorporate 
into regenerated tissues (Vassilopoulos, Wang et al. 2003; Wang, Willenbring et 
al. 2003). We next determined the recruitment of MSCs to the prostate during 
regrowth. We generated primary cultured MSCs from adult chicken -actin-GFP 
mouse bone marrow (Phinney, Kopen et al. 1999). The MSC trilineage 
differentiation potential was verified. The MSCs were shown to differentiate into 
adipocytes, as indicated with oil red-O staining, chondrocytes indicated with 
alcian blue staining, and osteocytes indicated by alkaline phosphatase staining  
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Figure 23. BMDCs incorporated into the prostate during regrowth. 
Immunofluorescence staining localized GFP-BMDCs in green with prostate 
markers in red. DAPI staining in blue indicates nuclear DNA. A) GFP-BMDCs co-
express the prostate lineage marker, androgen receptor, in red. B) GFP-BMDCs 
co-express the prostate basal epithelial marker, p63, in red. C) GFP-BMDCs co-
express the prostate luminal epithelial marker, cytokeratin 8, in red. D) GFP-
BMDCs show minimal co-expression of the hematopoietic marker, CD45, in red. 
96 
 
 
 
 
 
 
Figure 24. MSCs were functionally verified. Functional assays verified tri-
lineage differentiation potential of mesenchymal stem cells after culturing for 
three weeks. Adipogenic differentiation was verified by staining with Oil Red-O; 
lipid droplets stained a red color. Chondrogenic differentiation was verified by 
staining with alcian blue; matrix sulfated proteoglycans stained a turquoise blue 
color. Osteogenic differentiation was verified by alkaline phosphatase staining; 
osteogenic cells stained a deep fuschia color. 
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(Figure 24). The multipotential MSCs were tested for the expression of known 
chemokine receptors. As expected, the MSCs expressed CCR5, CCR2, and 
CXCR4. Next, we measured the expression of corresponding chemokines in 
prostates during regrowth, to determine a mechanism for MSC homing. We 
isolated RNA from castrated prostates and castrated prostates given 
testosterone for three days. CCL5 was confirmed to be elevated 2.6-fold during 
prostate regrowth (ANOVA, p = 0.0224) compared to castrated controls. 
However, CCL2 and SDF-1 were not significantly elevated during regrowth. 
Thus, the CCR5-CCL5 chemokine signaling axis is a potential mechanism for 
MSC recruitment during prostate regrowth.  
GFP-tagged MSCs were injected into mice to identify MSC recruitment to 
the prostate. We used intact or castrated host mice that were given exogenous 
testosterone for zero or three days, correlating with the highest level of BMDC 
recruitment. We then monitored MSC recruitment by GFP immunohistochemical 
staining and found a pattern similar to that seen with BMDC recruitment (Figure 
25). The GFP-MSCs were recruited to intact prostates at low levels (mean = 7.25 
cells per field of view).  Castrated mice had elevated MSC recruitment to the 
epithelial compartment of the prostate (mean = 25.75). Further elevation in MSC 
recruitment was observed following three days of testosterone supplementation 
(mean = 38.55). Importantly, examination of other tissues of the same mice (liver, 
intestine) revealed no detectible GFP-MSCs. Thus, the bone marrow derived 
MSC population could selectively incorporate into the prostate during regrowth.  
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Figure 25. MSCs were recruited to the prostate during regrowth. GFP 
immunohistochemistry was performed to stain GFP-MSCs (brown) that were 
recruited to the prostates of mice at the indicated time points during regrowth. 
Intact prostates had low basal recruitment of MSCs. Castrated prostates had 
increased MSC recruitment. Castrated prostates supplemented with exogenous 
testosterone for three days showed the greatest increase in MSC recruitment.  
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The fusion or transdifferentiation of MSC is reported in other model systems 
(Lee, Kuo et al. 2004; Dan and Yeoh 2008).  
We tested the potential of using MSC cell fusion or differentiation as a 
mechanism for targeting genetic material to CRPC. We used chicken -actin-
GFP mice as hosts for MSCs obtained from FSP1-Cre/Rosa26 mice. The 
development of FSP1-Cre/Rosa26 mice enabled MSC lineage tracing through 
the expression of -galactosidase. Prostates of castrated mice were visualized 
by confocal fluorescent microscopy following three days of testosterone 
supplementation. We identified prostate epithelial cells that co-expressed GFP 
with -galactosidase as an indication of fusion of the MSCs to the prostate 
epithelia (Figure 26). We calculated the percentage of recruited MSCs shown to 
undergo fusion at 48.9% (n= 5 mice, 20 fields of view).  
 
MSCs are recruited to human CRPC and enhance Wnt signaling in the tumor 
epithelia 
 To further explore the role of MSCs in CRPC growth and their potential for 
targeted therapy, we used the C4-2B human CRPC cell line, well characterized 
to grow as xenografts in castrated host mice (Thalmann, Anezinis et al. 1994). 
Based on the documented importance of Wnt signaling in CRPC (Terry, Yang et 
al. 2006; Verras and Sun 2006), we stably transduced C4-2B cells with a 
TCF/LEF responsive luciferase reporter lentivirus. This allowed us to monitor 
canonical Wnt activity within the tumor epithelia. We then transduced MSCs with 
either GFP adenovirus as a control or SFRP2 adenovirus. We hypothesized that  
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Figure 26. MSCs fused to the prostate during regrowth. Rosa26-expressing 
MSCs were injected into castrated GFP mice supplemented with exogenous 
testosterone for three days. Confocal microscopy showed colocalization of -
galactosidase-expressing MSCs with GFP prostate ducts. -galactosidase-
expressing MSCs were stained with red and shown in black and white. GFP-
expressing prostate ducts were stained in green and shown in black and white. 
Nuclear DNA was stained blue with TO-PRO-3 stain and shown in black and 
white. A merged color panel shows the colocalization of the red MSCs with green 
prostate epithelia, indicated by the overlay of yellow color and counterstained 
blue nuclei. 
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MSCs could home to C4-2B tumors and secrete SFRP2 to inhibit tumor 
progression. To generate the CRPC model, we orthotopically grafted C4-2B cells 
into each of the anterior lobes of SCID mouse prostates. The experimental 
timeline is summarized (Figure 27A). After ten days of tumor growth, the host 
mice were castrated. Serum testing indicated continued expression of PSA in 
C4-2B tumor bearing mice following castration, as expected. To test the efficacy 
of MSCs as a therapeutic tool for CRPC, we subsequently injected host mice 
with vehicle, GFP-transduced MSCs, or SFRP2-transduced MSCs and harvested 
the tumors five days after castration.  
After harvesting the C4-2B tumors, we measured TCF/LEF-luciferase 
activity, proliferation, and apoptosis. Analysis of luciferase expression from the 
lysed tumors revealed that mice given GFP-MSCs showed a 24-fold increase of 
canonical Wnt activity within the C4-2B tumor epithelia compared to controls 
(Figure 27B). Tumors from mice injected with SFRP2-MSCs had no difference in 
canonical Wnt activity compared to controls. This surprising finding suggested 
that five days following castration, wild type MSCs contribute to CRPC by 
enhancing Wnt signaling activity. Manipulating the MSCs to secrete SFRP2 
caused reduced proliferation and elevated apoptosis associated with increased 
necrosis within the tumors.  
H&E staining indicated focal areas of necrosis in control C4-2B tumors and in 
mice given GFP-MSCs (Figure 27C, D). The C4-2B tumors in mice given 
SFRP2-MSCs had comparatively greater areas of necrosis (Figure 27E). Tumor 
proliferation was analyzed by immunohistochemical localization of  
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Figure 27. GFP-MSCs recruited to human CRPC xenografts enhanced Wnt 
signaling. The experimental setup is summarized in the timeline (Figure 27A). 
C4-2B cells were orthotopically injected into the prostates of SCID mice. After 10 
days the mice were castrated and MSCs were given 24hours following 
castration. The tumors were harvested five days following castration. TOP-Flash 
luciferase activity was measured in C4-2B tumors (Figure 27B). GFP-MSCs 
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increased Wnt activity within the tumors by 24-fold compared to control 
uninjected tumors. SFRP2-MSCs suppressed Wnt activity to basal levels. C4-2B 
tumors were sectioned and stained histological analysis five days following 
castration. H&E staining shows some necrosis in C4-2B tumors without MSCs 
(Figure 27C). Necrosis was also seen with GFP-MSCs (Figure 27D), and 
increased necrosis was seen with SFRP2-MSCs (Figure 27E). Phosphorylated 
histone-H3 staining was used to stain tumors for mitotic proliferation. Basal levels 
of proliferation were seen in tumors without MSCs (Figure 27F). There was no 
difference in proliferation of tumors with GFP-MSCs (Figure 27G), and 
proliferation was significantly decreased in tumors with SFRP2-MSCs (p value = 
0.0069, Figure 27H). TUNEL staining shows levels of apoptosis. Areas of 
necrosis were avoided in quantitating TUNEL positive cells. Basal levels of 
apoptosis were seen in tumors without MSCs (Figure 27I), similar to tumors with 
GFP-MSCs (Figure 27H), and a significant increase in apoptosis was seen in 
tumors with SFRP2-MSCs (p value = 0.0066, Figure 27J). 
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phosphorylated histone-H3, indicating cells undergoing mitotic division (Figure 
27F-H). The mitotic rates of control and GFP-MSC-associated tumors were 
similar (Figure 27D, E). However, the mitotic rate in SFRP2-MSC-associated 
tumors was significantly lower than in control tumors (p value =0.0069, Figure 
27F). We next analyzed apoptosis in these tumors using TUNEL staining (Figure 
27G-I). Control and GFP-MSC-associated tumors had similar apoptotic cell 
numbers (Figure 27G, H). However, SFRP2-MSC tumors had a significant 
increase in apoptotic cells (p value = 0.0066, Figure 27I). Together, we found 
MSC recruitment to CRPC xenografts to support Wnt signaling and the targeted 
antagonism of Wnt signaling by MSCs can potentiate reduced tumor growth. 
  
Discussion 
 
Recruited BMDCs enhanced tumor progression through paracrine Wnt 
signaling. We found that the highest levels of BMDC recruitment occurred during 
prostate regrowth at three days. Interestingly, previous reports indicated that the 
highest level of prostate proliferation also occur three days following testosterone 
re-introduction, suggesting that peak tissue remodeling corresponds to greatest 
recruitment of BMDCs. This was to be expected, since BMDCs include 
inflammatory responsive cells such as leukocytes and macrophages, associated 
with clearing dead cells. However, this study demonstrated that a sub-population 
of BMDCs, MSCs, are recruited to potentiate re-growth. MSCs may provide 
growth factors that aid cancer progression in this complex signaling 
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microenvironment (Figure 28). We were able to employ MSC to target regrowing 
prostate tissue and deliver SFRP2, antagonizing Wnt-mediated tumor 
progression.  
Based on the microarray analysis of the Tgfbr2fspKO CRPC mouse model, 
(Table 2) and xenografted human CRPC C4-2B cells (Figure 27) it is likely that 
MSCs were recruited during regrowth through the CCL5-CCR5 axis. To broaden 
our understanding of mechanisms of CRPC, signaling pathway alterations based 
on LCM-microarray from Tgfbr2fspKO compared to Tgfbr2floxE2/floxE2 mouse stroma 
were analyzed. Interestingly, many more chemokines were upregulated than 
downregulated in the Tgfbr2fspKO prostate stroma. Of particular interest, CCL5 had 
a 70-fold increase in Tgfbr2fspKO stroma (Table 2). CCL5 is known to be 
upregulated in prostate cancer (Vaday, Peehl et al. 2006). It has also been 
shown to be a potent recruiter of BMDCs, including MSCs (Xu, Bian et al. 2009). 
A significant alteration of chemokine signaling within the tumor microenvironment 
was likely to result in BMDC recruitment. The multiple co-morbidities of the 
Tgfbr2fspKO mice (Bhowmick, Chytil et al. 2004; Li, Placencio et al. 2008; 
Placencio, Sharif-Afshar et al. 2008; Boomershine, Chamberlain et al. 2009) 
prevented us from generating chimeric mice using these as the host to track 
BMDC recruitment to the prostate. Therefore, we looked at recruitment during 
prostate regrowth in wild type mice as a way to understand this aspect of CRPC. 
We demonstrated how the recruited mesenchymal stem cells home to and 
contribute to CRPC by enhancing Wnt signaling within the tumor epithelia. Using 
MSCs as a delivery tool for secreted frizzled related protein 2 suppressed the  
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Figure 28. MSCs contribute to CRPC. This diagram represents a transformed 
prostate gland in CRPC. The rounded turquoise rectangles indicate the epithelial 
cells with an irregular nuclear size. The stroma is indicated with the pink half 
moon shapes, which surrounds the ducts and is being invaded by the 
transformed epithelia. Red and blue half moon shapes indicate recruited MSCs. 
The red MSCs represent the endogenous MSCs, which we showed enhance Wnt 
signaling in CRPC. The blue MSCs represent exogenous MSCs that express 
SFRP-2, antagonizing Wnt signaling in the CRPC. 
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enhanced Wnt signaling in the tumor epithelia to effectively increase apoptosis. 
MSCs may be used to deliver other gene therapeutics to enable CRPC 
regression. Using MSCs as a targeted delivery tool is also a way to avoid the 
toxicity associated with other less specific therapies. When targeting signaling 
pathways that have systemic effects, such as Wnt, it is especially necessary to 
avoid widespread repercussions. 
We showed that MSCs incorporate themselves into the prostate epithelia 
through fusion. It is likely that the total number of recruited MSCs is over-
estimated due to the experimental conditions of administering one million MSCs. 
However, the percentage of recruited MSCs observed to undergo fusion (48.9%), 
is likely similar to endogenous fusion events, respectively. Other studies have 
demonstrated how hematopoietic stem cells incorporate into the gastrointestinal 
epithelia through fusion during inflammation and proliferation (Rizvi, Swain et al. 
2006). Prostate injury from vaccinia virus infection can cause inflammation and 
glandular disruption, resulting in BMDC reconstitution of 4% of the prostate 
epithelium (Palapattu, Meeker et al. 2006).  Other studies have shown BMDCs 
recruited to and then incorporate into resulting epithelial tissues found in lung, 
liver, skin, heart, and gastrointestinal tract (Krause, Theise et al. 2001; Kawada, 
Fujita et al. 2004; Li, Stoicov et al. 2006). Cancer recurrence is linked to cell 
fusion (Dittmar, Nagler et al. 2009). CRPC cells have properties including 
increased drug resistance, increased resistance to apoptosis, and enhanced 
malignancy that are known to result from cells that have undergone cell fusion 
(Dittmar, Nagler et al. 2009).  We did not rule out the possibility of 
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transdifferentiation into prostate epithelial lineages. The chicken -actin-GFP 
mice used in the fusion experiment had focal expression of GFP in the prostate. 
Therefore, the presence of -galactosidase expressing MSCs in the absence of 
GFP could indicate transdifferentiation of the MSCs that incorporated into the 
prostate epithelia or fusion that we could not visualize due to the lack of GFP 
expression in those prostate epithelial cells. It is possible that both fusion and 
transdifferentiation are mechanisms of MSC incorporation into the prostate 
epithelia. Others have suggested that cancer stem cells may arise from the 
fusion of BMDCs with cancer cells, giving rise to cells more capable of evading 
immune control. While our study could not look at every possibility, we 
demonstrated the involvement of MSCs in the cancer microenvironment and the 
possibility of using MSCs to deliver therapeutic genes to control prostate cancer. 
In the C4-2B xenograft studies, the recruitment of MSCs enhanced Wnt 
activity within the tumors. However, there was little effect on proliferation, 
apoptosis, or tumor size in C4-2B xeongrafts in the presence or absence of MSC 
recruitment. This may be because C4-2B cells express high levels of Wnt ligands 
endogenously, masking the Wnt expression by the MSCs. This led us to 
hypothesize that MSCs may have a greater influence on androgen dependent 
tumors with lower amounts of Wnt that would be more sensitive to additional Wnt 
produced in the prostate microenvironment. By understanding how these MSC 
act upon cancer cells and contribute to the tumor microenvironment, we could 
learn to manipulate these cells to counteract their cancer promoting effects. We 
had some success in suppressing C4-2B tumor proliferation and promoting 
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apoptosis with MSC-targeted SFRP2 expression. However, we did not observe a 
significant reduction in tumor size. Targeting Wnt signaling is just one route for 
suppressing cancer progression. An approach targeting multiple signaling 
pathways is likely to be more effective in this late stage of cancer progression to 
provide a lasting effect on tumor size. 
 Collectively, these studies demonstrated BMDCs are involved in prostate 
regrowth and cancer progression. BMDCs, and in particular MSCs, are recruited 
to tissues undergoing active remodeling, including the cancer microenvironment. 
Given the innate cancer-homing capabilities of MSCs, it may be possible to use 
these cells to treat CRPC with therapeutic gene delivery.  
 
110 
CHAPTER IV 
 
CONCLUDING DISCUSSION 
 
Resident and recruited stroma contribute to castrate resistant prostate 
cancer. The prostate tumor microenvironment, as demonstrated in these studies, 
is greatly influenced by TGF-, Wnt, and androgen signaling (Table 3). These 
studies highlight Wnt signaling as a common pathway in CRPC that is influenced 
by resident stromal cells or recruited mesenchymal stem cells. The loss of TGF- 
signaling in Tgfbr2fspKO mice resulted in the enhanced production of Wnt ligands 
in the resident stroma. In addition to increased monocyte, macrophage, and 
leukocytes recruited there were also likely MSCs being recruited although this 
was not confirmed in these studies. These MSCs would also add to the Wnt 
produced in the prostate stromal microenvironment to activate epithelial Wnt 
signaling resulting in castrate resistance. Androgen ablation would select for 
castrate resistant epithelia, coupled with the transient elevation of TGF- and 
Wnt signaling will perpetuate the wound healing response to attract BMDCs to 
the tumor microenvironment. This would enhance the chemokine signaling in the 
tumor microenvironment and cause fusion of MSCs to tumor epithelia resulting in 
more aggressive cancer and enhanced metastasis. This „cancer wound‟ will 
never „heal‟ and Wnt signaling will ensue. The tumor epithelia will have increased 
proliferation as a result of enhanced Wnt signaling, castrate resistance, and 
uncontrolled growth. Simultaneously, BMDC recruitment will continue to further  
111 
 
Table 3. Summary of stromal associated events during CRPC. The major 
regulatory pathway with alterations are in the left column. The effects resulting 
from the pathways are described in the two columns on the right as they pertain 
to the resident or recruited stroma. As indicated, there are many overlapping 
effects between signaling pathways. 
Change in 
Regulatory 
Pathway 
Associated with  
Resident Stroma 
Associated with  
Recruited Stroma 
Loss of TGF-   PIN lesions and 
adenocarcinoma 
leading to castrate 
resistance of the 
epithelia 
 Enhanced recruitment 
of BMDCs  
 Increased monocytes, 
macrophage, 
leukocytes 
     Likely also increased T 
cells, B cells, MSCs 
Increased Wnt    Castrate resistance of 
epithelia by paracrine 
resident stroma 
 Castrate resistance of 
epithelia by paracrine 
recruited MSCs 
Loss of  
Androgens 
(castration) 
   Regression of normal 
epithelia with selection 
for castrate resistant 
epithelia 
   Transient elevation of 
TGF- and Wnt 
signaling 
  Wound healing 
response and 
increased 
inflammatory/ 
chemokine signaling to 
recruit BMDCs 
  
   Increased chemokine 
signaling   
Replacement of 
Androgens 
(castration + 
testosterone) or 
Adaptation to Low 
Levels of 
Androgens 
   Regrowth of castrate 
resistant epithelia 
   Increased chemokine 
signaling 
   More aggressive 
cancer 
   Will lead to metastasis 
 Regrowth/ Remodeling 
of the prostate 
enhances BMDC 
recruitment 
 Increased chemokine 
signaling 
 More aggressive 
cancer 
 Enhances metastasis 
 Increased MSC 
recruitment to enhance 
Wnt signaling 
 
 
112 
sustain the cancer resulting in a perpetual loop. Modulating Wnt signaling is a 
target for CRPC therapy as these studies have demonstrated. Further targets will 
also need to be identified, as our studies have shown the complex crosstalk 
between signaling pathways in CRPC development and progression.  
At the present time, we are unable to adequately study non-canonical Wnt 
signaling as it is altered by stromal TGF- and androgen signaling. Bicalutamide 
transiently elevated non-canonical Wnt-5a expression in Tgfbr2floxE2/floxE2 and 
Tgfbr2fspKO stromal cells (Figure 14). Most studies in the prostate look at the 
canonical Wnt pathway involving -catenin, since this pathway is more defined. 
Studying non-canonical Wnt signaling is complicated and not well defined. 
Therefore, these studies focused on understanding canonical Wnt signaling as 
multiple tools are available. It will be important to understand how the non-
canonical PCP, JNK, or calcium Wnt pathways are affected by androgens. These 
pathways are likely to affect CRPC. Interestingly, SFRP-2 is known to inhibit 
canonical Wnt-3a and also non-canonical Wnt-5a (Hou, Tan et al. 2004). These 
were two of the Wnt genes altered in our Tgfbr2floxE2/floxE2 and Tgfbr2fspKO stromal 
cells after bicalutamide treatment. It is likely that effects we saw with SFRP-2 
also affected non-canonical Wnt signaling in ways that we were not able to 
assess. This suggests further crosstalk between non-canonical Wnt and 
androgen signaling in CRPC. Recent evidence also suggests that non-canonical 
Wnt signaling is important in MSC differentiation. Specifically, Wnt-5a was shown 
to oppose Wnt-3a in regulating the MSC differentiation potential (Baksh and 
Tuan 2007). This is increasingly important as castrate resistant C4-2B human 
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prostate cancer cells are known to have more stem cell-like properties compared 
to the androgen-dependent LNCaP cells from which they were derived. The role 
of canonical and non-canonical Wnt signaling with respect to TGF- and 
androgen signaling is important for future CRPC therapy. 
 We continue to understand the complexities of prostate cancer. Once 
CRPC develops in this late stage, cancer mortality is primarily due to metastases 
that have arisen from the primary tumor. We still do not understand how these 
metastases develop and disseminate. It is likely that metastatic cells have 
entered circulation since the first development of the primary tumor. Therefore, 
even before diagnosis, metastases are frequently colonizing the bone and other 
organs. They may remain dormant for many years, with the event that triggers 
subsequent growth at distant sites unknown. In many cases, these metastatic 
cells remain inactive and benign, but those few that are activated to proliferate 
are problematic.  
 When thinking of treatments for CRPC, we must keep in mind treatments 
for castrate resistant bone metastases. It has been shown that MSCs can home 
to tumors. MSCs home to tumors using a similar mechanism as that used by 
immune cells. MSCs are thought to possess chemotactic properties similar to 
inflammatory cells that enable their recruitment to sites of inflammation or tissue 
remodeling. These properties also allow them to evade immune detection when 
circulating throughout the body. For this reason, directed therapy with MSCs is 
likely to cause less systemic effects and allow a more targeted approach to 
tumors. The bone marrow is the natural home for MSCs, thus directed targeting 
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to the metastases in the bone marrow would be an option worth exploring. These 
cells would survive and even thrive in their natural environment, and this would 
give them an advantage over foreign prostate cancer epithelial cells. It would be 
extremely important to fully understand how MSCs proliferate and contribute to 
their microenvironments. For use as a therapeutic, MSCs would need to be 
engineered in a way to target cancer cells while not enhancing their growth or the 
tumor microenvironment, yet maintaining the natural balance within the bone 
microenvironment. As we used in our studies, SFRP-2 over-expression is a 
candidate to start with, though it is probable that multiple gene targets would be 
most effective. Wnt signaling is also a major pathway in the bone 
microenvironment. Thus, it may be more effective to focus on individual Wnt 
target genes rather than inhibiting all Wnt ligands with SFRP-2. More studies will 
be necessary, but MSC directed therapy may be effective for bone metastases. 
  As we continue to study how cancer develops we must understand the 
role our immune system plays to regulate this process. It is known that in most 
people there are microscopic cancers. Determining how the cancer is kept 
dormant and small would be of use to future treatments to allow us to treat 
cancer. Studies have also used other cell types besides MSCs as therapeutic 
agents. These include dendritic cells and T cells to target tumor antigens. 
Foreign pathogen immune response elicits CD4+ and CD8+ T cells. It is known 
that TGF- in the tumor microenvironment has immunosuppressive effects. To 
circumvent this, CD4+ and CD8+ T cells were engineered to express dominant 
negative TRII (Gorelik and Flavell 2001). Mouse tumor models showed that 
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these engineered T cells, by not responding to the immunosuppressive effects of 
TGF- in the tumor microenvironment, were able to inhibit and eradicate tumor 
growth. These studies suggest that it is possible to eradicate cancer with our own 
immune defense system, albeit with alterations to boost a necessary response. 
Our immune system is unique to each individual, as unique as each cancer. 
Thus, it makes sense that we must study cancer from the perspective that a 
given cancer can behave very differently in individuals with a slight alteration in 
their genetic makeup. In addition, ageing negatively impacts the ability of the 
immune system to fight cancer (Gruver, Hudson et al. 2007), thus a major reason 
that cancer incidence increases with age (Yancik and Ries 2000). As we 
understand how our immune system keeps our bodies healthy we can use this 
information to help fight cancer. A greater understanding of our immune system 
would allow us to target specific tumors. 
 These studies have demonstrated the importance of understanding the 
complex tumor microenvironment to effectively treat prostate cancer. As 
described, CRPC development and progression is not well understood, which is 
evident in the fact that there are no current therapies for late stages of cancer. 
The development of CRPC was classified into five main categories: 1) 
hypersensitive AR, 2) promiscuous AR, 3) outlaw AR, 4) bypass AR, and 5) 
lurker cells (Figure 4) (Feldman and Feldman 2001). Based on our studies, I 
propose adding a sixth category: stromal paracrine signaling. Herein, these 
studies have described how the prostate resident stroma influences epithelial 
androgen responsiveness and development of CRPC through paracrine Wnt 
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signaling. In addition, recruited stroma such as MSCs were shown to increase 
Wnt signaling in CRPC through paracrine signaling. More studies must be 
conducted in order to understand all the components- besides TGF-, androgen, 
and Wnt signaling- that influence the ever changing tumor microenvironment 
from the site of the primary cancer to the metastatic site(s). As suggested, when 
developing effective therapy it is necessary to keep in mind not only the 
cancerous epithelia, but the resident and recruited stromal cell types that are 
heterogeneous in nature with respect to innate characteristics and androgen 
status. The need for multimodality treatment approaches for prostate and other 
carcinomas is evident. 
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CHAPTER V 
 
FUTURE DIRECTIONS 
 
These studies using the Tgfbr2fspKO mouse model have expanded the 
current knowledge on the development and progression of CRPC. However, the 
limited lifespan of the Tgfbr2fspKO mice (less than two months) coupled with their 
weak state as they age make long-term studies impossible. Of importance is the 
need to know if the transformation of epithelial PIN lesions and eventually 
prostate adenocarcinoma is unique to the FSP-1 expressing fibroblast lineage in 
which the FSP-1 promoter is driven by Cre. Collagen-1Cre-ER mice have a 
Cre-ER fusion protein driven by the Collagen-1 promoter that specifically binds 
tamoxifen. Collagen-1-2 is expressed ubiquitously in all stromal cells. 
Rosa/Tgfbr2floxE2/floxE2 mice were crossed with collagen-1Cre-ER mice to 
generate Rosa/Tgfbr2ColFlox mice. Treatment of the dam of these mice starting 
after birth of the pups (on days 1, 3, 5) by intra-peritoneal injection with tamoxifen 
results in the production of viable and healthy Rosa/Tgfbr2ColTKO mice with 
detectable Tgfbr2 recombination by PCR. It will be important to characterize 
these new mice to determine if the knockout of TRII in Collagen-1-2 
expressing stromal cells is similar to that of FSP-1 expressing stromal cells.  
Preliminary studies suggest the phenotypes are similar. The 
Rosa/Tgfbr2ColTKO mice develop PIN lesions and areas of focal adenocarcinoma 
as they age. Preliminary castration studies, however, have been difficult with 
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older mice aged to 32 weeks. In many mice, the testes for an unknown reason 
are firmer and appear to have overgrown into the adjacent scrotum tissue. 
Excision is complicated by the testicles not having a defined shape and not being 
easily released from the scrotum. Future studies would likely benefit from 
chemical castration with bicalutamide or another pharmacologic agent to avoid 
incomplete removal of the testes. Confirmation will further support the importance 
of the stroma in prostate cancer initiation, progression, and development of 
CRPC. In addition, pathologic analysis of the testicular tissue may reveal 
development of testicular hyperplasia, cancer, or some other abnormality of 
importance resulting from the long-term knockout of stromal TGF- signaling.  
Stem cell/ progenitor cell studies with the Rosa/Tgfbr2ColTKO mice would 
highlight the importance of the stroma with respect to the stem cell niche. We 
have analyzed Tgfbr2fspKO mice labeled with long term incorporation of BrdU to 
track progenitor cells in the prostates. These mice, as the Tgfbr2fspKO/TOPGal 
studies alluded to, have increased BrdU- positive progenitor stem cells. It would 
be interesting to analyze the incorporation of BrdU in Rosa/Tgfbr2ColTKO prostates 
compared to their controls as they develop adenocarcinoma. Even more 
interesting would be to analyze the BrdU-positive cells in relation to recruited 
BMDCs or MSCs. Coupled by the comparison of fusion to progenitor stem cells 
versus non-progenitors in prostate cancer. The Rosa/Tgfbr2ColTKO mice would 
serve as an ideal host to analyze the prostates at various stages of cancer 
progression. 
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It is important to understand the mechanism that leads to loss of TRII in 
prostate cancer stroma. Previous studies have suggested methylation as the 
most likely mechanism (Kim, Im et al. 2000). It is thought that repression of 
Tgfbr2 is responsible for tumor resistance to TGF-. Methylation of CpG islands 
in the promoter region of Tgfbr2 represses transcriptional activity. Other studies 
have also shown that Tgfbr2 is regulated by distinct ets family members. The ets 
family consists of potent transcriptional transactivators. Disregulation of the ets 
family has been shown to lead to loss of TRII expression (Macleod, Leprince et 
al. 1992). Microsatellite instability also led to TRII frameshift mutations in colon 
cancer (Markowitz, Wang et al. 1995; Samowitz and Slattery 1997). There are 
many potential mechanisms that can lead to loss of TRII expression. It is 
important to determine the mechanism of prostate stromal loss of TRII.  
It is possible that compensatory signaling by Activin and its cognate 
receptors may provide Smad protein activity similar to TGF-. Activin is known to 
be active in fibroblasts. Thus, in the Tgfbr2fspKO stromal cells it is likely that Activin 
signaling acts as a compensatory signaling pathway. This may be why many 
organs and tissues in the Tgfbr2fspKO mouse do not have an overt phenotype. In 
Tgfbr2fspKO mouse prostate tissues, phosphorylated Smad2 and Smad3 
immunohistochemistry revealed focal expression (data not shown). The knockout 
was not in 100% of the prostate fibroblasts, thus some of this signaling was due 
to the incomplete knockout. It is also likely that this was also due to 
compensatory Activin signaling also leading to phosphorylated Smad2 and 
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Smad3 activation. Further studies are needed to verify the involvement of Activin 
signaling in the Tgfbr2fspKO stromal cells. 
The majority of our studies on BMDC and MSC recruitment were 
performed in wild type mice. It will be important to determine how BMDCs and 
MSCs are recruited in transgenic mouse models of prostate cancer. With 
improved imaging techniques, monitoring recruitment from the stages of cancer 
initiation to development of CRPC will be important. This will provide insight for 
BMDC therapy to determine when inhibition of recruitment would be the most 
effective in treating cancer. It is likely that different populations of BMDCs are 
recruited at different stages of progression. Monitoring individual populations of 
BMDCs in tumor progression may allow us to determine which populations 
enhance or inhibit tumor growth. In addition, we must determine what cues 
trigger their recruitment. If Rosa/Tgfbr2ColTKO mice are confirmed to develop 
CRPC, BMDC recruitment studies could be performed as they remain healthy 
into late adulthood. Recruitment of BMDCs to tumors is likely to give insight on 
designing targeted therapies for CRPC. 
CRPC is thought to arise from clonal selection following androgen ablation 
through various mechanisms previously described. Cancer recurrence is linked 
to cell fusion (Dittmar, Nagler et al. 2009). CRPC cells have properties including 
increased drug resistance, increased resistance to apoptosis, and enhanced 
malignancy that are known to result from cells that have undergone cell fusion. It 
is not clear which cell types may fuse to give rise to cancer stem cells with 
resistance to androgen ablation. Fusion has been shown to occur in an effort to 
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restore degenerated tissue function. The tumor microenvironment on its own, but 
even more prevalent during cancer therapy, has tissue destruction and 
remodeling, increased inflammation, and thus enhanced recruitment of various 
BMDCs. This suggests that androgen ablation regimens to treat prostate cancer 
will promote recruitment of BMDCs capable of fusion with cancer cells that may 
actually lead to more aggressive cancer upon recurrence. Fusion of MDA-MB435 
breast cancer cells has been shown to occur spontaneously (Duelli and Lazebnik 
2003). Evidence of cell fusion in humans also exists. Renal cell carcinoma 
patients that received bone marrow transplants had donor DNA within their 
cancer cells suggesting fusion occurred (Chakraborty, Lazova et al. 2004; 
Yilmaz, Lazova et al. 2005). Increasing evidence for fusion in cancer suggests 
that BMDC therapy may inevitably result in cell fusion with tumor cells or other 
cells within the body. It may require extra safeguards that need to be engineered 
into immune cell therapies such as a self-destruct function. BMDCs or immune 
cells would need to induce apoptosis once their task was completed or after a 
given period of time to avoid acquiring mutations.  
Concomitant with age, the immune system becomes less effective at 
fighting off illness and disease. Cancer incidence therefore increases with age. 
One could envision that as our understanding of the immune system and other 
processes increases we will develop preventative measures to boost our immune 
systems as a way to eradicate cancer as it develops. Preventative maintenance 
for automobiles consists of regular oil changes and tune-ups to keep vehicles 
running smoothly. Analogous to automobile maintenance, “immune system tune-
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ups” could keep the body in better shape to detect and prevent cancer. As 
discussed previously, dominant negative-TRII CD4+ and CD8+ T cells were 
able to eradicate cancer in mice. Using this principle, protective measures may 
consist of periodically boosting our immune systems by harvesting our own cells, 
altering them to detect and destroy cancer, and giving them back to elicit a 
protective immune response to cancer. This concept may be years away from 
inception as a preventive measure given our limited knowledge. However, clinical 
trials are currently being investigated to treat tumors and diseases in this 
manner. At late stage cancer progression when patients have no other 
alternatives, immune therapy may be desirable even without foresight for long-
term side effects. As described in these studies, the use of MSCs as a potential 
targeted therapy for CRPC shows promise with correct manipulation to inhibit 
tumor progression. As our knowledge expands, treatment and preventative 
options increase. The future for cancer treatment holds promise. 
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